Oncotelic Therapeutics, Inc. 424B5, filed Jul 8, 2011: Prospectus filed pursuant to Rule 424(b)(5)
Table of Contents
Filed Pursuant to Rule 424(b)(5)
File No. 333-155371
File No. 333-155371
PROSPECTUS SUPPLEMENT
(To Prospectus dated December 1, 2008)
(To Prospectus dated December 1, 2008)
OXiGENE, INC.
$3,100,000
Common Stock
$3,100,000
Common Stock
We are offering shares of our common stock having an aggregate offering price of up to
$3,100,000 from time to time through our sales agent, McNicoll, Lewis & Vlak LLC (“MLV”). These
sales, if any, will be made pursuant to the terms of an At Market Issuance Sales Agreement entered
into between us and our sales agent on July 21, 2010, a copy of which was filed with the Securities
and Exchange Commission as an exhibit to our Current Report on Form 8-K on July 21, 2010, and is
incorporated herein by reference.
Our common stock is listed on The NASDAQ Capital Market under the symbol “OXGN.” On May 12, 2011,
the last reported sale price of our common stock was $5.60 per share and on July 7, 2011, the last
reported sale price of our common stock was $2.43. The market value of our outstanding common
equity held by non-affiliates as of the date of this prospectus supplement was approximately
$66,778,085, based on 13,329,229 shares of outstanding common stock, of which 11,924,658 shares
were held by non-affiliates, and based on the closing sale price of our common stock on May 12,
2011 of $5.60. As of the date of this prospectus supplement, we have sold securities in an
aggregate offering amount of $19,156,051 pursuant to General Instruction I.B.6. of Form S-3 during
the 12 calendar month period that ends on, and includes, the date of this prospectus supplement.
Sales of shares of our common stock under this prospectus, if any, may be made in privately
negotiated transactions and/or any other method permitted by law, including sales deemed to be an
“at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, which
includes sales made directly on The NASDAQ Capital Market, the existing trading market for our
common stock, or sales made to or through a market maker other than on an exchange. The sales agent
will make all sales using commercially reasonable efforts consistent with its normal trading and
sales practices, on mutually agreeable terms between the sales agent and us.
Unless we and our sales agent otherwise agree, we will pay our sales agent a commission fee of up
to 5% of each sale of common stock to be sold pursuant to this prospectus. Any other fee
arrangement or commission amount to be received by the sales agent will be disclosed in a separate
prospectus supplement for such shares. The net proceeds to us that we receive from sales of our
common stock will depend on the number of shares actually sold and the offering price for such
shares. Based on the trading price of our common stock, our current public float and the absence of
a minimum offering amount provided for under the sales agreement, we may not be able to raise the
full $3,100,000 in gross proceeds contemplated by this prospectus supplement. The actual proceeds
to us will vary.
In connection with the sales of common stock on our behalf, the sales agent will be deemed an
“underwriter” within the meaning of the Securities Act of 1933, as amended, and the compensation of
the sales agent will be deemed to be underwriting commissions or discounts. We have agreed to
provide indemnification and contribution to the sales agent against certain liabilities, including
liabilities under the Securities Act of 1933, as amended.
Table of Contents
Our business and an investment in our securities involve significant risks. These risks are
described under the caption “Risk Factors” beginning on page S-9 of this prospectus supplement and
page 6 of the accompanying prospectus. You should carefully consider these risk factors before
making an investment decision.
Neither the Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the accuracy or adequacy of this prospectus
supplement or the accompanying prospectus. Any representation to the contrary is a criminal
offense.
McNicoll, Lewis & Vlak LLC
The
date of this prospectus supplement is July 8, 2011.
TABLE OF CONTENTS
Prospectus Supplement
Prospectus Supplement
| S-1 | ||||
| S-9 | ||||
| S-18 | ||||
| S-19 | ||||
| S-19 | ||||
| S-20 | ||||
| S-21 | ||||
| S-21 | ||||
| S-22 | ||||
| S-22 | ||||
Prospectus |
||||
| 3 | ||||
| 3 | ||||
| 6 | ||||
| 6 | ||||
| 6 | ||||
| 7 | ||||
| 7 | ||||
| 8 | ||||
| 13 | ||||
| 15 | ||||
| 17 | ||||
| 18 | ||||
| 18 | ||||
| 19 | ||||
| 19 |
This document is in two parts. The first part is the prospectus supplement, which describes the
specific terms of the securities we are offering and also adds to and updates information contained
in the accompanying prospectus and the documents incorporated by reference into the accompanying
prospectus. The second part, the accompanying prospectus, including the documents incorporated by
reference, provides more general information. Generally, when we refer to this prospectus, we are
referring to both parts of this document combined. This prospectus supplement and the accompanying
prospectus and the documents incorporated by reference herein and therein are part of a shelf
registration statement that we filed with the Securities and Exchange Commission, or SEC. Under the
shelf registration process, we may offer from time to time shares of our common stock and other
securities up to an aggregate amount of $50,000,000, of which this offering is a part. This
prospectus supplement and the accompanying prospectus and the documents incorporated by reference
herein and therein include important information about us, our securities being offered and other
information you should know before investing. You should read this prospectus supplement, the
accompanying prospectus, the documents incorporated by reference in this prospectus supplement and
the accompanying prospectus and any related free writing prospectus that we authorized to be
delivered to you, as well as the additional information described under “Where You Can Find More
Information” on page 19 of the accompanying prospectus before investing in our securities.
S-i
Table of Contents
To the extent there is a conflict between the information contained in this prospectus supplement,
on the one hand, and the information contained in the accompanying prospectus or in any document
incorporated by reference that we filed with the SEC before the date of this prospectus supplement,
on the other hand, you should rely on the information in this prospectus supplement. If any
statement in one of these documents is inconsistent with a statement in another document having a
later date — for example, a document incorporated by reference in the accompanying prospectus —
the statement in the document having the later date modifies or supersedes the earlier statement.
You should rely only on the information contained in this prospectus supplement, the accompanying
prospectus, any related free writing prospectus that we authorized to be distributed to you and the
documents incorporated by reference herein and therein. We have not, and the sales agent has not,
authorized anyone to provide you with information that is different. If anyone provides you with
different or inconsistent information, you should not rely on it. We are offering to sell and
seeking offers to buy shares of our securities only in jurisdictions where offers and sales are
permitted. Persons outside the United States who come into possession of this prospectus must
inform themselves about, and observe any restrictions relating to, the offering of the common stock
and warrants to purchase common stock and the distribution of this prospectus outside the United
States. The information contained in, or incorporated by reference to, this prospectus supplement,
the accompanying prospectus, and any related free writing prospectus that we authorized to be
delivered to you, is accurate only as of the respective dates of those documents, regardless of the
time of delivery of this prospectus supplement or of any sale of our securities. Our business,
financial condition, results of operations and prospects may have changed since those dates. You
should not consider this prospectus supplement or the accompanying prospectus to be an offer or
solicitation relating to the securities in any jurisdiction in which such an offer or solicitation
relating to the securities is not authorized. Furthermore, you should not consider this prospectus
supplement or the accompanying prospectus to be an offer or solicitation relating to the securities
if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for
you to receive such an offer or solicitation.
S-ii
Table of Contents
PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights certain information about us, this offering and information appearing
elsewhere in this prospectus supplement, in the accompanying prospectus and in the documents we
incorporate by reference. This summary is not complete and does not contain all of the information
that you should consider before investing in our securities. The following summary is qualified in
its entirety by, and should be read in conjunction with, the more detailed information and
financial statements and notes thereto appearing elsewhere in this prospectus supplement and the
accompanying prospectus. Before you decide to invest in our securities, to fully understand this
offering and its consequences to you, you should carefully read the entire prospectus supplement
and the accompanying prospectus, including the risk factors beginning on page S-9 of this
prospectus supplement, and the consolidated financial statements and related notes included in this
prospectus supplement, the accompanying prospectus and the documents incorporated by reference
herein and therein.
Our Company
Our Business
We are a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer
and eye diseases. Our primary focus is the development of product candidates referred to as
vascular disrupting agents, or VDAs, that selectively disable and destroy abnormal blood vessels
that provide solid tumors a means of growth and survival and also are associated with visual
impairment in a number of ophthalmological diseases and conditions. To date, more than 400 subjects
have been treated with ZYBRESTAT™, our lead candidate, in human clinical trials, and the drug
candidate has generally been observed to be well-tolerated.
In February 2011, our board of directors voted unanimously to implement a 1:20 reverse stock split
of our common stock, following authorization of the reverse split by a shareholder vote on December
21, 2010. The reverse split became effective on February 22, 2011. All of the share and per share
amounts discussed in this Prospectus Supplement have been adjusted to reflect the effect of this
reverse split.
We expect cash on hand as of March 31, 2011, plus the proceeds of our at-the-market equity offering
sales agreement with McNicoll, Lewis & Vlak LLC, or MLV, received in the second and third quarters of 2011 to
fund our operations through the third quarter of fiscal 2012. If we are unable to access additional
funds when needed, we will not be able to continue the development of our product candidates and
could be required to delay, scale back or eliminate some or all of our development programs and
other operations. Such funding may not be available to us on acceptable terms, or at all. If we
fail to secure additional financing before the end of the third quarter of fiscal 2012, we would be forced to
cease all of our clinical and other activities. Any additional equity financing, which may not be
available to us or may not be available on favorable terms, most likely will be dilutive to our
current stockholders and debt financing, if available, may involve restrictive covenants. If we
access funds through collaborative or licensing arrangements, we may be required to relinquish
rights to some of our technologies or product candidates that we would otherwise seek to develop or
commercialize on our own, on terms that are not favorable to us. Our ability to access capital when
needed is not assured and, if not achieved on a timely basis, will materially harm our business,
financial condition and results of operations. These conditions raise substantial doubt about our
ability to continue as a going concern. The Report of Independent Registered Public Accounting Firm
at the beginning of the Consolidated Financial Statements section in our Annual Report on Form 10-K
for the year ended December 31, 2010 includes a going concern explanatory paragraph.
ZYBRESTAT for Oncology
We are currently pursuing the development of ZYBRESTAT, a reversible tubulin binding agent that
works by disrupting the network of blood vessels, or vasculature, within tumors, also referred to
as vascular disruption. ZYBRESTAT selectively targets the existing abnormal vasculature found
specifically in most solid tumors and causes endothelial cells in that vasculature to become round
and block the flow of blood to the tumor. The downstream tumor environment is then deprived of
oxygen, and the resulting restriction in blood supply kills the cells in the central portion of the
tumor. Based on ZYBRESTAT’s positive activity observed in animal models, we have conducted multiple
clinical trials of ZYBRESTAT in a variety of tumor types. We have recently completed a Phase 2/3
clinical trial of ZYBRESTAT in patients with anaplastic thyroid cancer (ATC) and have ongoing
clinical trials of ZYBRESTAT in patients with non-small cell lung cancer (NSCLC) and ovarian
cancer.
FACT (fosbretabulin in anaplastic cancer of the thyroid) trial — Phase 2/3 study with ZYBRESTAT in
anaplastic thyroid cancer (ATC)
In earlier Phase 1 studies of ZYBRESTAT in ATC, clinical investigators observed several objective
responses in treatment with ZYBRESTAT, including a complete response lasting more than 13 years, in
patients with ATC. A subsequent Phase 2 study in 26 ATC patients showed a 23% rate of one year
survival in a disease where median expected survival of patients is approximately 3-4 months from
the time of diagnosis and fewer than 10% of patients are typically alive at one year.
S-1
Table of Contents
Based on this encouraging data, we completed a Special Protocol Assessment, or SPA, process with
the U.S. Food and Drug Administration, or FDA, in 2007, for a Phase 2/3 study, which we refer to as
the FACT trial, in which ZYBRESTAT was to be evaluated in 180 patients as a potential treatment for
ATC. ATC is a highly aggressive and lethal malignancy for which there are currently no approved
therapeutics and extremely limited treatment options.
ZYBRESTAT was awarded orphan drug status by the FDA and the European Commission in the European
Union for the treatment of advanced ATC and for the treatment of medullary, Stage IV papillary and
Stage IV follicular thyroid cancers. The FDA also granted Fast Track designation to ZYBRESTAT for
the treatment of regionally advanced and/or metastatic ATC.
The primary endpoint for the FACT trial is overall survival. Eligible patients with histologically
or cytologically confirmed ATC were randomized either to the treatment arm of the study, in which
they received ZYBRESTAT in combination with the chemotherapeutic agents carboplatin and paclitaxel,
or to the control arm of the study, in which they received only carboplatin and paclitaxel. Central
pathology review by external pathologists not associated with the study was utilized to confirm the
histological diagnosis.
The FACT trial began enrolling patients in 2007. A total of 40 clinical sites in 11 countries
participated in this clinical study, which was conducted in accordance with good clinical practice
guidelines and the SPA. Due to the rarity of the disease and the fact that most of the patients
screened for the study either died or no longer met the trial’s inclusion criteria, the enrollment
period spanned more than twice the planned 18 month period. As a result of both the length of the
enrollment period and financial constraints affecting us, in February 2010, we chose to continue to
treat and follow all 80 patients who were enrolled in the Phase 2/3 FACT clinical trial in ATC in
accordance with the SPA, but to stop further enrollment.
Initial data from this trial was presented at both the 14th International Thyroid Congress on
September 12, 2010 in Paris, France and the 35th European Society of Medical Oncology Congress on
October 11, 2010 in Milan, Italy. At these meetings, we reported data suggesting a one-month
benefit in overall survival in patients receiving ZYBRESTAT in combination with chemotherapy. Of
particular note was the fact that the one year survival rate was more than doubled from 9% to 23%
for patients receiving chemotherapy plus ZYBRESTAT. The additional data we presented in October
2010 also included some pre-defined subgroup analyses that confirmed the overall survival benefit
initially observed, and also indicated that ZYBRESTAT improved the survival of patients with the
most advanced stages of the disease, as well as patients who had been heavily pretreated with
surgery, radiation or chemotherapy.
Julie Sosa, M.D., Associate Professor of Surgery and of Medicine at Yale University and primary
investigator in the Phase 2/3 study, presented final data from the trial at the American Society of
Clinical Oncology (ASCO) conference in Chicago, Illinois in June 2011. Dr. Sosa presented data
reflecting a median overall survival (OS) time of 5.2 months for patients who received ZYBRESTAT
and chemotherapy compared with 4.0 months for patients receiving chemotherapy alone, representing a
28% reduction in the risk of death for patients receiving ZYBRESTAT and chemotherapy. For patients
treated with ZYBRESTAT and chemotherapy, the data suggested that the likelihood of being alive at
six months was 48% compared with 35% for patients treated with the control arm regimen. At one
year, the data suggested that the likelihood of being alive was 26% for patients treated with
ZYBRESTAT and chemotherapy compared with 9% for patients treated with chemotherapy alone. As in
other studies, ZYBRESTAT appeared to be well tolerated.
The FDA has been informed that enrollment in this study was halted at 80 patients and that we
expected that the SPA would no longer be applicable. The orphan drug status and the expedited
review designations have not been affected by the halted enrollment in the Phase 2/3 study. On
March 16, 2011, we met with the FDA to discuss the results of this study and a potential path
forward. The FDA indicated at the meeting that the data from the FACT trial are suggestive of
possible clinical activity that may warrant continued development, and that to seek regulatory
approval, we should plan to conduct an additional clinical trial with a survival endpoint. The FDA
also confirmed that, as we expected, the SPA that had been agreed upon at the start of the study is
no longer in effect.
FALCON (fosbretabulin in advanced lung oncology) trial — randomized, controlled Phase II study
with ZYBRESTAT in non-small cell lung cancer
We are currently evaluating ZYBRESTAT in a 63-patient, randomized, controlled Phase 2 clinical
trial, which we refer to as the FALCON trial, as a potential first-line treatment for non-small
cell lung cancer, or NSCLC. In the FALCON trial, patients are randomized either to the treatment
arm of the study, in which they receive ZYBRESTAT (CA4P) in combination with the chemotherapeutic
agents, carboplatin and paclitaxel, and bevacizumab, a drug that interferes with blood vessel
growth, or angiogenesis, or to the control arm of the study, in which they receive a standard
combination regimen of carboplatin, paclitaxel and bevacizumab. The
primary endpoint of the study will be time to progression. We believe that this study will
suggest a benefit of ZYBRESTAT in NSCLC therapy. We further believe these data could be used to
design a pivotal registration program with ZYBRESTAT in NSCLC and more generally, provide clinical
validation supporting further evaluation of ZYBRESTAT in combination with commonly used
anti-angiogenic therapeutics that act by selectively inhibiting a particular blood vessel growth
path, namely, the vascular endothelial growth factor, or VEGF, pathway.
S-2
Table of Contents
We presented an update of the safety and clinical activity data for this trial at the European
Organization for Research and Treatment of Cancer symposium in November 2010 in Berlin, Germany.
The updated interim data showed that the median time to progression
for patients receiving ZYBRESTAT plus bevacizumab and chemotherapy was 9.5 months, compared with a
median time to progression of 8.8 months for patients receiving bevacizumab and chemotherapy alone.
Of the patients in the study arm (ZYBRESTAT combined with bevacizumab and carboplatin/paclitaxel
chemotherapy), 50% achieved a partial response, compared with the control arm (bevacizumab and
chemotherapy) of the trial, where only 38% of patients achieved a partial response. The combination
regimen including ZYBRESTAT was observed to be well-tolerated with no significant cumulative
toxicities when compared with the control arm of the study.
Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles
and primary investigator in the study, presented the overall survival data from this study at the
ASCO conference in Chicago, Illinois in June 2011. Dr. Garon’s updated analysis, conducted
approximately 11 months after the enrollment of the last patient in June 2010, showed that the
combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT arm)
appeared to be well-tolerated with no significant cumulative toxicities when compared with the
control arm of the study. In addition, a pre-specified subgroup analysis showed meaningful
improvements in median time to progression for patients with poor performance status (ECOG
Performance Status 1). Poor performance status in this context refers to patients who have
additional medical complications, suffer from additional illnesses such as emphysema or diabetes,
or who may be taking other medications. While the median time to progression for the overall
patient population was similar in both arms of the study, 8.6 months for the ZYBRESTAT arm compared
with 9.0 months on the control arm, an analysis of the patient strata showed that patients with
poor performance status who received ZYBRESTAT in addition to bevacizumab and chemotherapy achieved
a median time to progression of 9.8 months compared with only 3.8 months for patients in this same
subgroup on the control arm of the study with a hazard ratio of 0.51, reflecting a 49% reduction in the risk of progression. This data, suggesting that
the addition of ZYBRESTAT may benefit patients with a poorer performance status, is preliminary at
this stage. However, several attendees at the conference shared our view that more study is
warranted by the meaningful improvements suggested among patients with poor performance status.
ZYBRESTAT in ovarian cancer
On June 1, 2009, we reported positive final data from an investigator-sponsored Phase 2 study of
ZYBRESTAT and carboplatin plus paclitaxel chemotherapy in patients with platinum-resistant ovarian
cancer at the 2009 ASCO Annual Meeting. Of 44 patients enrolled in the study, 11 (25%) had
confirmed partial responses as determined by the Gynecologic Cancer Inter Group (GCIG) response
criteria, i.e., response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125)
criteria. An additional 4 patients had unconfirmed partial responses, and stable disease responses
were reported in an additional 16 patients. The combination regimen of ZYBRESTAT and carboplatin
plus paclitaxel chemotherapy was observed to be well-tolerated with approximately half of the
patients completing all 6 cycles of therapy.
Based on the results of this Phase 2, single-arm, two-stage study, in February 2011, we announced
that we have entered into a Cooperative Research and Development Agreement (CRADA) with the
National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program (CTEP) to collaborate on the
conduct of a randomized Phase 2 trial of ZYBRESTAT in combination with bevacizumab in up to 110
patients with relapsed, platinum-sensitive ovarian cancer. Under the terms of the agreement, we
will provide ZYBRESTAT to NCI for an NCI-sponsored study conducted by the Gynecologic Oncology
Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The
aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance
anti-tumor effects and further delay tumor progression when compared to bevacizumab alone. Investigators initiated
enrollment in this Phase 2 study in the first half of 2011. The primary endpoint of the study will be
progression-free survival, with results expected to become available in early 2013.
The June 2011 ASCO meeting in Chicago, Illinois included an announcement that the addition of
Avastin ®
(bevacizumab) to a chemotherapy regimen reduces the risk of progression in patients with
platinum-sensitive ovarian cancer. This is of particular interest to OXiGENE in view of the NCI /
CTEP Phase 2 study of ZYBRESTAT in combination with bevacizumab for platinum-sensitive ovarian
cancer patients, and we are encouraged to see additional data from other studies supporting use of
bevacizumab in platinum-sensitive ovarian cancer patients.
Further development of our ongoing clinical trials will depend on continuing analysis and results
of these ongoing clinical studies and our cash resources at that time.
Possible areas for future development
We believe that, if successful, the ongoing ZYBRESTAT for oncology clinical trial program will
establish a compelling rationale for further development of ZYBRESTAT as a treatment for:
| • | aggressive and difficult-to-treat solid tumors; |
S-3
Table of Contents
| • | use in combination with chemotherapy in a variety of solid tumors, particularly those in which carboplatin and/or paclitaxel chemotherapy are commonly used; and | ||
| • | use in combination with commonly used drugs, such as bevacizumab, that interfere with blood vessel growth, or angiogenics, in various solid tumor indications. |
We believe these areas for potential further development collectively represent a significant unmet
medical need and thus a significant potential commercial market opportunity that includes cancers
of the thyroid, ovary, kidney, liver, head and neck, breast, lung, skin, brain, colon and rectum.
OXi4503, a unique, second generation VDA for oncology indications
We are currently pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a
treatment for certain solid tumor types and, as a more recent development, for the treatment of
myeloid leukemias. We believe that OXi4503 is differentiated from other VDAs by its dual-action
activity: in addition to having potent vascular disrupting effects, OXi4503 is unique in that
certain enzymes in the human body can help convert it to a form of chemical that has direct tumor
cell killing effects. We believe this unique property may result in enhanced anti-tumor activity in
certain tumor types as compared with other VDA drug candidates. Based on data from preclinical
studies, we believe that OXi4503 may have enhanced activity in tumor types with relatively high
levels of the enzymes that facilitate the conversion of OXi4503 to the form of chemical that kills
tumor cells. These tumor types include hepatocellular carcinoma, melanoma, and leukemias of the
myeloid lineage. In preclinical studies, OXi4503 has shown potent anti-tumor activity against solid
tumors and acute myeloid leukemia models, both as a single agent and in combination with other
cancer treatment modalities.
We have completed a Phase 1 clinical trial of OXi4503 in patients with advanced solid tumors
sponsored by Clinical Research United Kingdom. In collaboration with us, Professor Gordon Rustin
and colleagues from the Mount Vernon Cancer Research Centre, UK and other institutions in the
United Kingdom, reported positive final data from this study at the 2010 ASCO Annual Meeting. In
this study, 45 patients with advanced solid tumors who had declined or were unresponsive to
standard treatment were treated with escalating doses of OXi4503. Partial responses were observed
in two patients with epithelial ovarian cancer and stable disease was observed in 9 patients.
OXi4503 was also observed to be well-tolerated in this study. To date, OXi4503 has been observed to
have a manageable side-effect profile similar to that of other agents in the VDA class, potential
single-agent clinical activity, and effects on tumor blood flow and tumor metabolic activity, as
determined with several imaging modalities. We also evaluated escalating doses of OXi4503 in an
OXiGENE-sponsored Phase 1b trial, initiated in the first quarter of 2009 in patients with solid
tumors with hepatic involvement. This study confirmed the recommended dose established in the first
Phase 1 study. We have completed the final analysis of this study and look forward to either
publishing the data or presenting it at an upcoming medical meeting.
Based on the results of preclinical studies published in the journal Blood in September 2010 that
show OXi4503 has potent activity against acute myelogenous leukemia (AML) in animal models, we
entered into a clinical trial agreement pursuant to which investigators at the University of
Florida initiated an investigator sponsored Phase 1 study of OXi4503 in patients with AML or
myelodysplastic syndrome (MDS) in May 2011. This open-label, dose-escalating study for the
treatment of up to 36 patients is being conducted in patients with relapsed or refractory AML and
MDS and will evaluate the safety profile, maximum tolerated dose and biologic activity of OXi4503
in these patients. We expect that initial indications of biologic activity from this study may be
available as early as the first half of 2012.
The general direction of future development of OXi4503 — for solid tumors or hematologic
indications — will depend on the outcome of the analysis of both the solid tumor studies and the
study in AML, as well as available financial resources and potential partnering activities.
ZYBRESTAT for Ophthalmology
In addition to developing ZYBRESTAT as an intravenously administered therapy for oncology
indications, we have undertaken an ophthalmology research and development program with ZYBRESTAT
with the ultimate goal of developing a topical formulation of ZYBRESTAT for ophthalmological
diseases and conditions that are characterized by abnormal blood vessel growth within the eye that
result in loss of vision. Previously, we reported results at the 2007 annual meeting of the
Association for Research in Vision and Ophthalmology, or ARVO, from a Phase 2 study in patients
with myopic macular degeneration in which all patients in the study met the primary clinical
endpoint of vision stabilization at three months after study entry.
In December 2010, we completed a randomized, double-masked, placebo-controlled Phase 2
proof-of-mechanism trial, which we refer to as the FAVOR trial, with a single dose of
intravenously-administered ZYBRESTAT in patients with polypoidal choroidal vasculopathy (PCV), a
form of choroidal neovascularization, which is a condition where new blood vessels form in the
choroid, a part of the eye, and which can lead to vision loss and, ultimately, blindness. Current
therapies, including approved drugs that interfere with blood vessel growth, known as
anti-angiogenesis, appear to provide limited benefit. We believe that the architecture of the
abnormal
S-4
Table of Contents
vasculature in certain eye tissues, namely the retina and choroid, which contribute to PCV
patients’ loss of vision, may be particularly susceptible to treatment with a VDA such as
ZYBRESTAT.
We believe that PCV represents an attractive target indication and development pathway for
ZYBRESTAT. Unlike wet age-related macular degeneration, an indication for which several
anti-angiogenic drugs are approved or prescribed off-label, conducting clinical studies of
ZYBRESTAT in patients with ophthalmologic indications not yet approved for treatment with such
anti-angiogenic drugs could potentially prove to reduce development time and expense. The
objectives of the FAVOR trial and the ongoing preclinical program of ZYBRESTAT in ophthalmology are
to:
| • | determine the therapeutic utility of ZYBRESTAT in PCV, and visualize the effect of ZYBRESTAT on the vasculature of the polyps associated with PCV; | ||
| • | determine blood concentrations of drug required for activity in humans and thereby estimate, with the benefit of preclinical data, an appropriate dose of topically-administered ZYBRESTAT to be evaluated in subsequent human clinical studies; and | ||
| • | further evaluate the feasibility of developing a topical formulation of ZYBRESTAT for ophthalmological indications. |
Findings from the Phase 2 study, including effects on retinal thickness and retinal bleeding, are
expected to be presented at a future ophthalmology meeting.
We believe that a safe, effective and convenient topically-administered anti-vascular therapeutic
would have advantages over currently approved anti-vascular, ophthalmological therapeutics, many of
which must be injected directly into patients’ eyes, in some cases on a chronic monthly basis.
For this purpose we have been developing a potential “minitab” topical formulation of ZYBRESTAT
which has demonstrated attractive pharmacokinetic and safety properties and efficacy in destroying
abnormal vasculature in a rat choroidal melanoma model following administration in the eye. We
believe that a topical formulation would enhance our partnering opportunities to further develop
ZYBRESTAT in diseases of the eye.
To date, we have completed preclinical testing that indicated that ZYBRESTAT has activity in six
different preclinical ophthalmology models, including a model in which ZYBRESTAT was combined with
an approved drug that interferes with blood vessel growth, or anti-angiogenic agents. We have also
completed multiple preclinical studies suggesting that ZYBRESTAT, when applied topically to the
surface of the eye at doses that appear to be well-tolerated, penetrates to the retina and choroid
in quantities that we believe should be sufficient for therapeutic activity.
We are also evaluating the requirements for additional preclinical toxicology and efficacy studies
with ZYBRESTAT for topical ophthalmological formulations to better position the program for
partnering. Further development of this program will depend on the outcome of our evaluation of
these requirements and available financial resources.
S-5
Table of Contents
Company Background
We are a Delaware corporation, incorporated in 1988 in the state of New York and
reincorporated in 1992 in the state of Delaware, with our principal corporate office in the United
States at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 (telephone: (650)
635-7000, fax: (650) 635-7001). We also have an office at 300 Bear Hill Road, Waltham,
Massachusetts 02451. Our Internet address is www.OXiGENE.com. Our annual reports on Form 10-K,
quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those reports,
are available to you free of charge through the “Investors” section of our web site as soon as
reasonably practicable after such materials have been electronically filed with, or furnished to,
the Securities and Exchange Commission. Information contained on our web site does not form a part
of this prospectus.
Corporate
We are committed to a disciplined financial strategy and as such maintain a limited employee and
facilities base, with development, scientific, finance and administrative functions, which include,
among other things, product development, regulatory oversight and clinical testing. Our research
and development team members typically work on a number of development projects concurrently.
Accordingly, we do not separately track the costs for each of these research and development
projects to enable separate disclosure of these costs on a project-by-project basis. We conduct
scientific activities pursuant to collaborative arrangements with universities. Regulatory and
clinical testing functions are generally contracted out to third-party, specialty organizations.
Risks Affecting Us
Our business is subject to numerous risks as discussed more fully in the section entitled “Risk
Factors” immediately following this prospectus supplement summary. We have not received regulatory
approval for any of our products and have not successfully launched or earned commercial revenues
from any of our products. If we do not successfully commercialize our products, we will be unable
to achieve our business objectives. In addition, the reported results of our early-stage clinical
trials may not be indicative of results that would be achieved in later-stage clinical trials
involving larger and more diverse patient populations. We may not be able to replicate our
preclinical trial results in humans. Preliminary preclinical and clinical trial results presented
in this prospectus supplement are also subject to further review and auditing by us. As of March
31, 2011, we had an accumulated deficit of approximately $208,563,000. We expect to continue to
incur significant losses over the next several years, and we may never become profitable. Even
assuming we are able to replicate our preclinical trial results in humans, the time and expense
required to complete the development of our products and receive regulatory approval for any of our
products is significant and we cannot guarantee that we will have access to sufficient funding to
successfully commercialize our products or achieve our business objectives.
S-6
Table of Contents
The Offering
Issuer: |
OXiGENE, Inc. | |
Common Stock offered by us
pursuant to this prospectus
supplement |
Up to $3,100,000 in gross proceeds | |
Common Stock outstanding before
the offering |
13,329,229 shares | |
Common Stock outstanding after
the offering |
14,604,949 shares1 | |
Maximum Gross Proceeds |
$3,100,000 | |
Manner of Offering |
Sales of shares of our common stock | |
| under this prospectus supplement, if | ||
| any, may be made in privately | ||
| negotiated transactions and/or any | ||
| other method permitted by law, | ||
| including sales deemed to be an “at | ||
| the market” offering as defined in | ||
| Rule 415 under the Securities Act of | ||
| 1933, as amended, which includes | ||
| sales made directly on The NASDAQ | ||
| Capital Market, the existing trading | ||
| market for our common stock, or sales | ||
| made to or through a market maker | ||
| other than on an exchange. The sales | ||
| agent will make all sales using | ||
| commercially reasonable efforts | ||
| consistent with its normal trading | ||
| and sales practices, on mutually | ||
| agreeable terms between the sales | ||
| agent and us. See "Plan of | ||
| Distribution." | ||
Sales Agent |
McNicoll, Lewis & Vlak LLC | |
Risk Factors |
See “Risk Factors” beginning on page | |
| S-9 of the prospectus supplement and | ||
| page 6 of the accompanying prospectus | ||
| for a discussion of the factors that | ||
| you should carefully consider before | ||
| deciding to invest in our common | ||
| stock. | ||
Use of Proceeds |
We intend to use the net proceeds of | |
| this offering to fund our internal | ||
| research and development programs, | ||
| preclinical studies and clinical | ||
| trials with respect to our VDAs, the | ||
| development of new product candidates | ||
| and for general corporate purposes. | ||
| See “Use of Proceeds” on page S-19. | ||
NASDAQ Capital Market symbol |
OXGN |
Footnote 1: The number of shares of our common stock to be outstanding immediately after this
offering is based on (a) 1,275,720 shares of our common stock to be issued in this
offering, assuming a stock price of $2.43 per share, the last reported sales price of our common
stock on July 7, 2011, and that the full $3,100,000 of shares
offered are sold, and (b) 13,329,229
shares of our common stock outstanding as of July 7, 2011, and excludes the following shares as of
such date:
S-7
Table of Contents
| • | 306,674 shares of common stock issuable upon the exercise of stock options outstanding as of July 7, 2011 at a weighted average exercise price of $29.15 per share; | |
| • | 12,500 shares of common stock issuable upon the exercise of warrants issued in February 2008 at a weighted average exercise price of $54.80 per share; | |
| • | 140,625 shares of common stock issuable upon the exercise of the five-year warrants issued in July 2009 at an exercise price of $42.00 per share; and | |
| • | 180,012 shares of common stock reserved for future awards under our stock plan and employee stock purchase plan. |
S-8
Table of Contents
RISK FACTORS
Investing in our securities involves a high degree of risk. You should carefully review and
consider the following risk factors and in the sections entitled “Risk Factors” contained in our
most recent annual report on Form 10-K and quarterly report on Form 10-Q, which have been filed
with the SEC and are incorporated by reference in this prospectus supplement and the accompanying
prospectus, as well as any updates thereto contained in subsequent filings with the SEC or in any
free writing prospectus and all other information contained in this prospectus supplement and the
accompanying prospectus and incorporated by reference into the prospectus before purchasing our
securities. The risks and uncertainties described below are not the only ones facing us. Additional
risks and uncertainties that we are unaware of, or that we currently deem immaterial, also may
become important factors that affect us. If any of the following risks occur, our business,
financial condition or results of operations could be materially and adversely affected. In that
case, the trading price of our common stock could decline, and you may lose some or all of your
investment.
Risks Related to Our Business
We will be required to raise additional funds to finance our operations and remain a going concern;
we may not be able to do so when necessary, and/or the terms of any financings may not be
advantageous to us.
Our operations to date have consumed substantial amounts of cash. Negative cash flows from our
operations are expected to continue over at least the next several years. Our cash utilization
amount is highly dependent on the progress of our product development programs, particularly, the
results of our preclinical and clinical studies, the cost, timing and outcomes of regulatory
approval for our product candidates, the terms and conditions of our contracts with service
providers for these programs, and the rate of recruitment of patients in our human clinical trials.
In addition, the further development of our ongoing clinical trials will depend on upcoming
analysis and results of those studies and our cash resources at that time.
We expect cash on hand as of March 31, 2011, plus the proceeds of our at-the-market equity
offering sales agreement with McNicoll, Lewis & Vlak LLC, or MLV, received in the second and third quarters of
2011, to fund our operations through the third quarter of fiscal 2012. In order to remain a going
concern beyond the third quarter of fiscal 2012, we will require significant additional funding. Additional
funds to finance our operations may not be available on terms that we deem acceptable, or at all.
If we fail to secure financing before the end of the third quarter of fiscal 2012, we would be
forced to cease all of our clinical and other activities.
Our ongoing capital requirements will depend on numerous factors, including: the progress and
results of preclinical testing and clinical trials of our product candidates under development,
including ZYBRESTAT and OXi4503; the progress of our research and development programs; the time
and costs expended and required to obtain any necessary or desired regulatory approvals; the
resources, if any, that we devote to develop manufacturing methods and advanced technologies; our
ability to enter into licensing arrangements, including any unanticipated licensing arrangements
that may be necessary to enable us to continue our development and clinical trial programs; the
costs and expenses of filing, prosecuting and, if necessary, enforcing our patent claims, or
defending against possible claims of infringement by third-party patent or other technology rights;
the cost of commercialization activities and arrangements, if any, undertaken by us; and, if and
when approved, the demand for our products, which demand depends in turn on circumstances and
uncertainties that cannot be fully known, understood or quantified unless and until the time of
approval, including the range of indications for which any product is granted approval.
If we are unable to raise additional funds when needed, we will not be able to continue
development of our product candidates or we will be required to delay, scale back or eliminate some
or all of our development programs or cease operations. We may seek to raise additional funds
through public or private financing, strategic partnerships or other arrangements. Since July 21, 2010, we have raised an aggregate of $19,156,051 in proceeds under the at-the-market
equity offering sales agreement with MLV, which has resulted in substantial dilution to our existing
equity holders. We will be required to engage in additional financings in order to continue our
operations. Any additional equity financing will likely cause further dilution to our current stockholders and debt financing, if available, may
involve restrictive covenants. If we raise funds through collaborative or licensing arrangements,
we may be required to relinquish, on terms that are not favorable to us, rights to some of our
technologies or product candidates that we would otherwise seek to develop or commercialize. Our
failure to raise capital when needed will materially harm our business, financial condition and
results of operations. These conditions raise substantial doubt about our ability to continue as a
going concern. The Report of Independent Registered Public Accounting Firm at the beginning of the
Consolidated Financial Statements section of our Annual Report on Form 10-K for the year ended
December 31, 2010 includes a going concern explanatory paragraph.
S-9
Table of Contents
We have a history of losses, and we anticipate that we will continue to incur losses in the future.
We have experienced net losses every year since our inception and, as of March 31, 2011, we
had an accumulated deficit of approximately $208,563,000. We anticipate continuing to incur
substantial additional losses over at least the next several years due to, among other factors, the
need to expend substantial amounts on our continuing clinical trials with respect to our VDA drug
candidates, technologies, and anticipated research and development activities and the general and
administrative expenses associated with those activities. We have not commercially introduced any
product and our potential products are in varying early stages of development and testing. Our
ability to attain profitability will depend upon our ability to develop products that are effective
and commercially viable, to obtain regulatory approval for the manufacture and sale of our products
and to license or otherwise market our products successfully. We may never achieve profitability,
and even if we do, we may not be able to sustain being profitable.
Due in part to our constrained financial resources, we may fail to select or capitalize on the most
scientifically, clinically or commercially promising or profitable indications or therapeutic areas
for our product candidates or those that are in-licensed.
We have limited technical, managerial and financial resources to determine the indications on which
we should focus the development efforts related to our product candidates. Due to our limited
available financial resources, we have had to curtail clinical development programs and activities
that might otherwise have led to more rapid progress of our product candidates through the
regulatory and development processes. For example, in February 2010 we announced a restructuring of
our clinical development programs. As a part of that restructuring, we stopped enrollment in our
FACT trial and have redirected available resources away from other clinical trial programs in favor
of those we believe to have the highest value. We may make incorrect determinations with regard to
the indications and clinical trials on which to focus the available resources that we do have. The
decisions to allocate our research, management and financial resources toward particular
indications or therapeutic areas for our product candidates may not lead to the development of
viable commercial products and may divert resources from better opportunities. Similarly, our
decisions to delay or terminate drug development programs may also cause us to miss valuable
opportunities. In addition, from time to time, we may in-license or otherwise acquire product
candidates to supplement our internal development activities. Those activities may use resources
that otherwise would have been devoted to our internal programs. We cannot assure you that any
resources that we devote to acquired or in-licensed programs will result in any products that are
superior to our internally developed products.
Our product candidates have not completed clinical trials, and may never demonstrate sufficient
safety and efficacy in order to do so.
Our product candidates are in an early stage of development. In order to achieve profitable
operations, we alone or in collaboration with others, must successfully develop, manufacture,
introduce and market our products. The time frame necessary to achieve market
S-10
Table of Contents
success for any individual product is long and uncertain. The products currently under development
by us will require significant additional research and development and extensive preclinical and
clinical testing prior to application for commercial use. A number of companies in the
biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials,
even after showing promising results in early or later-stage studies or clinical trials. Although
we have obtained some favorable results to-date in preclinical studies and clinical trials of
certain of our potential products, such results may not be indicative of results that will
ultimately be obtained in or throughout such clinical trials, and clinical trials may not show any
of our products to be safe or capable of producing a desired result. Additionally, we may encounter
problems in our clinical trials that will cause us to delay, suspend or terminate those clinical
trials. Further, our research or product development efforts may not be successfully completed, any
compounds currently under development by us may not be successfully developed into drugs, any
potential products may not receive regulatory approval on a timely basis, if at all, and
competitors may develop and bring to market products or technologies that render our potential
products obsolete. If any of these problems occur, our business would be materially and adversely
affected.
Our committed equity financing facility with Kingsbridge may not be available to us. If we elect to
make a draw down, we may be required to make additional “blackout” or other payments to
Kingsbridge, which may result in dilution to our stockholders.
On February 19, 2008, we entered into a Committed Equity Financing Facility, or CEFF, with
Kingsbridge Capital Limited, or Kingsbridge. The terms of the CEFF were amended in February 2010.
The CEFF entitles us to sell and obligates Kingsbridge to purchase, from time to time until May 15,
2012, shares of our common stock for cash consideration up to an aggregate of $40 million, subject
to certain conditions and restrictions. Kingsbridge will not be obligated to purchase shares under
the CEFF unless certain conditions are met, which include a minimum price for our common stock; the
accuracy of representations and warranties made to Kingsbridge; compliance with laws; effectiveness
of the registration statement registering the shares issuable to Kingsbridge under the CEFF for
resale; and the continued listing of our stock on a principal market which includes The NASDAQ
Capital Market. In addition, Kingsbridge is permitted to terminate the CEFF if it determines that a
material and adverse event has occurred affecting our business, operations, properties or financial
condition and if such condition continues for a period of 10 days from the date Kingsbridge
provides us notice of such material and adverse event. If we are unable to access funds through the
CEFF, or if the CEFF is terminated by Kingsbridge, we may be unable to access capital on favorable
terms or at all.
We are entitled, in certain circumstances, to deliver a blackout notice to Kingsbridge to suspend
the use of the registration statement registering the shares issuable to Kingsbridge under the CEFF
for resale and prohibit Kingsbridge from selling shares under the prospectus. If we deliver a
blackout notice in the 15 trading days following the settlement of a draw down, or if the
registration statement is not effective in circumstances not permitted by the agreement, then we
must make a payment to Kingsbridge, or issue Kingsbridge additional shares in lieu of this payment,
calculated on the basis of the number of shares held by Kingsbridge (exclusive of shares that
Kingsbridge may hold pursuant to exercise of the Kingsbridge warrant) and the change in the market
price of our common stock during the period in which the use of the registration statement is
suspended. If the trading price of our common stock declines during a suspension of the
registration statement, the blackout or other payment could be significant.
Should we sell shares to Kingsbridge under the CEFF, or issue shares in lieu of a blackout payment,
such sale will have a dilutive effect on the holdings of our current stockholders, and may result
in downward pressure on the price of OXiGENE common stock. If OXiGENE draws down under the CEFF, we
will issue shares to Kingsbridge at a discount of up to 14% from the volume weighted average price
of our common stock. If OXiGENE draws down amounts under the CEFF when our share price is
decreasing, we will need to issue more shares to raise the same amount than if our stock price was
higher. Issuances in the face of a declining share price will have an even greater dilutive effect
than if OXiGENE’s share price was stable or increasing, and may further decrease OXiGENE’s share
price. We will not be eligible to sell shares to Kingsbridge under the CEFF if the closing price of
our common stock is below $0.75 per share.
We depend heavily on our executive officers, directors, and principal consultants and the loss of
their services would materially harm our business.
We believe that our success depends, and will likely continue to depend, upon our ability to retain
the services of our current executive officers, directors, principal consultants and others. The
loss of the services of any of these individuals could have a material adverse effect on our
business. In addition, we have established relationships with universities, hospitals and research
institutions, which have historically provided, and continue to provide, us with access to research
laboratories, clinical trials, facilities and patients. Additionally, we believe that we may, at
any time and from time to time, materially depend on the services of consultants and other
unaffiliated third parties. We cannot assure you that consultants and other unaffiliated third
parties will provide the level of service to us that we require in order to achieve our business
objectives.
Our industry is highly competitive, and our products may become technologically obsolete.
We are engaged in a rapidly evolving field. Competition from other pharmaceutical companies,
biotechnology companies and research and academic institutions is intense and expected to increase.
Many of those companies and institutions have substantially greater financial, technical and human
resources than we do. Those companies and institutions also have substantially greater experience
in
S-11
Table of Contents
developing products, in conducting clinical trials, in obtaining regulatory approval and in
manufacturing and marketing
pharmaceutical products. Our competitors may succeed in obtaining regulatory approval for their
products more rapidly than we do. Competitors have developed or are in the process of developing
technologies that are, or in the future may be, the basis for competitive products. We are aware of
at least one other company that currently has a clinical-stage VDA for use in an oncology
indication. Some of these competitive products may have an entirely different approach or means of
accomplishing the desired therapeutic effect than products being developed by us. Our competitors
may succeed in developing technologies and products that are more effective and/or cost competitive
than those we are developing, or that would render our technology and products less competitive or
even obsolete. In addition, one or more of our competitors may achieve product commercialization or
patent protection earlier than we do, which could materially adversely affect us.
We have licensed in rights to ZYBRESTAT, OXi4503 and other programs from third parties. If our
license agreements terminate, we may lose the licensed rights to our product candidates, including
ZYBRESTAT and OXi4503, and we may not be able to continue to develop them or, if they are approved,
market or commercialize them.
We depend on license agreements with third parties for certain intellectual property rights
relating to our product candidates, including patent rights. Currently, we have licensed in patent
rights from Arizona State University, or ASU, and the Bristol-Myers Squibb Company for ZYBRESTAT
and OXi4503 and from Baylor University for other programs. In general, our license agreements
require us to make payments and satisfy performance obligations in order to keep these agreements
in effect and retain our rights under them. These payment obligations can include upfront fees,
maintenance fees, milestones, royalties, patent prosecution expenses, and other fees. These
performance obligations typically include diligence obligations. If we fail to pay, be diligent or
otherwise perform as required under our license agreements, we could lose the rights under the
patents and other intellectual property rights covered by the agreements. While we are not
currently aware of any dispute with any licensors under our material agreements with them, if
disputes arise under any of our in-licenses, including our in-licenses from ASU and the
Bristol-Myers Squibb Company, and Baylor University, we could lose our rights under these
agreements. Any such disputes may or may not be resolvable on favorable terms, or at all. Whether
or not any disputes of this kind are favorably resolved, our management’s time and attention and
our other resources could be consumed by the need to attend to and seek to resolve these disputes
and our business could be harmed by the emergence of such a dispute.
If we lose our rights under these agreements, we may not be able to conduct any further activities
with the product candidate or program that the license covered. If this were to happen, we might
not be able to develop our product candidates further, or following regulatory approval, if any, we
might be prohibited from marketing or commercializing them. In particular, patents previously
licensed to us might after termination be used to stop us from conducting these activities.
We depend extensively on our patents and proprietary technology, and we must protect those assets
in order to preserve our business.
Although we expect to seek patent protection for any compounds we discover and/or for any specific
use we discovers for new or previously known compounds, any or all of them may not be subject to
effective patent protection. Further, the development of regimens for the administration of
pharmaceuticals, which generally involve specifications for the frequency, timing and amount of
dosages, has been, and we believe, may continue to be, important to our effort, although those
processes, as such, may not be patentable. In addition, the issued patents may be declared invalid
or our competitors may find ways to avoid the claims in the patents.
Our success will depend, in part, on our ability to obtain patents, protect our trade secrets and
operate without infringing on the proprietary rights of others. As of June 25, 2011, we were the
exclusive licensee, sole assignee or co-assignee of twenty-nine (29) granted United States patents,
fifteen (15) pending United States patent applications, three (3) pending Patent Cooperation Treaty
international patent applications, and granted patents and/or pending applications in several other
major markets, including the European Union, Canada and Japan. The patent position of
pharmaceutical and biotechnology firms like us are generally highly uncertain and involves complex
legal and factual questions, resulting in both an apparent inconsistency regarding the breadth of
claims allowed in United States patents and general uncertainty as to their legal interpretation
and enforceability. Accordingly, patent applications assigned or exclusively licensed to us may not
result in patents being issued, any issued patents assigned or exclusively licensed to us may not
provide us with competitive protection or may be challenged by others, and the current or future
granted patents of others may have an adverse effect on our ability to do business and achieve
profitability. Moreover, since some of the basic research relating to one or more of our patent
applications and/or patents were performed at various universities and/or funded by grants, one or
more universities, employees of such universities and/or grantors could assert that they have
certain rights in such research and any resulting products. Further, others may independently
develop similar products, may duplicate our products, or may design around our patent rights. In
addition, as a result of the assertion of rights by a third party or otherwise, we may be required
to obtain licenses to patents or other proprietary rights of others in or outside of the United
States. Any licenses required under any such patents or proprietary rights may not be made
available on terms acceptable to us, if at all. If we do not obtain such licenses, we could
encounter delays in product market introductions while our attempts to design around such patents
or could find that the development, manufacture or sale of products requiring such licenses is
foreclosed. In addition, we could incur substantial costs in defending
S-12
Table of Contents
ourselves in suits brought
against us or in connection with patents to which we hold licenses or in bringing suit to protect
our own patents against infringement.
We require employees, Scientific Advisory Board members, Clinical Trial Advisory Board members, and
the institutions that perform our preclinical and clinical trials to enter into confidentiality
agreements with us. Those agreements provide that all confidential information developed or made
known to the individual during the course of the relationship with us to be kept confidential and
not to be disclosed to third parties, except in specific circumstances. Any such agreement may not
provide meaningful protection for our trade secrets or other confidential information in the event
of unauthorized use or disclosure of such information.
If third parties on which we rely for clinical trials do not perform as contractually required or
as we expect, we may not be able to obtain regulatory approval for or commercialize our product
candidates.
We do not have the ability to independently conduct the clinical trials required to obtain
regulatory approval for our product candidates. We depend on independent clinical investigators
and, in some cases, contract research organizations and other third-party service providers to
conduct the clinical trials of our product candidates and expect to continue to do so. We rely
heavily on these parties for successful execution of our clinical trials, and we do not control
many aspects of their activities. Nonetheless, we are responsible for confirming that each of our
clinical trials is conducted in accordance with our general investigational plan and protocol.
Moreover, the FDA and corresponding foreign regulatory authorities require us and our clinical
investigators to comply with regulations and standards, commonly referred to as good clinical
practices, for conducting and recording and reporting the results of clinical trials to assure that
data and reported results are credible and accurate and that the trial participants are adequately
protected. Our reliance on third parties that we do not control does not relieve us of these
responsibilities and requirements. Third parties may not complete activities on schedule or may not
conduct our clinical trials in accordance with regulatory requirements or the respective trial
plans and protocols. The failure of these third parties to carry out their obligations could delay
or prevent the development, approval and commercialization of our product candidates or result in
enforcement action against us.
Our products may result in product liability exposure, and it is uncertain whether our insurance
coverage will be sufficient to cover all claims.
The use of our product candidates in clinical trials and for commercial applications, if any, may
expose us to liability claims, in the event such product candidates cause injury or disease, or
result in adverse effects. These claims could be made directly by health care institutions,
contract laboratories, patients or others using such products. Although we have obtained liability
insurance coverage for our ongoing clinical trials, this coverage may not be in amounts sufficient
to protect us from any product liability claims or product recalls which could have a material
adverse effect on our financial condition and prospects. Further, adverse product and similar
liability claims could negatively impact our ability to obtain or maintain regulatory approvals for
our technology and product candidates under development.
If we do not obtain required regulatory approvals, we will be unable to market and sell our product
candidates.
Our product candidates are subject to extensive governmental regulations relating to development,
clinical trials, manufacturing, and commercialization. Rigorous preclinical testing and clinical
trials and an extensive regulatory review and approval process are required to be successfully
completed in the United States and in many foreign jurisdictions before a new drug can be sold.
Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and
subject to unanticipated delays. The time required to obtain approval by the FDA is unpredictable
but typically exceeds five years following the commencement of clinical trials, depending upon the
complexity of the product candidate.
We have limited experience in conducting and managing the clinical trials necessary to obtain
regulatory approvals, including approval by the FDA. In connection with the clinical trials of our
product candidates, we face risks that:
| • | the product candidate may not prove to be safe and efficacious; | |
| • | patients may die or suffer serious adverse effects for reasons that may or may not be related to the product candidate being tested; | |
| • | the results of later-phase clinical trials may not confirm the results of earlier clinical trials; and | |
| • | the results may not meet the level of statistical significance or clinical benefit-to-risk ratio required by the FDA or other regulatory agencies for marketing approval. |
S-13
Table of Contents
Only a small percentage of product candidates for which clinical trials are initiated are the
subject of NDAs and even fewer receive approval for commercialization. Furthermore, even if we do
receive regulatory approval to market a product candidate, any such approval may be subject to
limitations such as those on the indicated uses for which we may market the product.
If clinical trials for our product candidates are prolonged, delayed or suspended, we may be unable
to commercialize our product candidates on a timely basis, which would require us to incur
additional costs and delay our receipt of any revenue from potential product sales.
We cannot predict whether we will encounter problems with any of our completed, ongoing or planned
clinical trials that will cause us or any regulatory authority to delay or suspend those clinical
trials or delay the analysis of data derived from them. A number of events, including any of the
following, could delay the completion of our other ongoing and planned clinical trials and
negatively impact our ability to obtain regulatory approval for, and to market and sell, a
particular product candidate:
| • | conditions imposed on us by the FDA or any foreign regulatory authority regarding the scope or design of our clinical trials; | |
| • | delays in obtaining, or our inability to obtain, required approvals from institutional review boards or other reviewing entities at clinical sites selected for participation in our clinical trials; | |
| • | insufficient supply of our product candidates or other materials necessary to conduct and complete our clinical trials; | |
| • | slow enrollment and retention rate of subjects in clinical trials; | |
| • | negative or inconclusive results from clinical trials, or results that are inconsistent with earlier results; | |
| • | serious and unexpected drug-related side effects; | |
| • | failure of our third-party contractors to comply with regulatory requirements or otherwise meet their contractual obligations to us. |
Commercialization of our product candidates may be delayed by the imposition of additional
conditions on our clinical trials by the FDA or any foreign regulatory authority or the requirement
of additional supportive studies by the FDA or any foreign regulatory authority. In addition,
clinical trials require sufficient patient enrollment, which is a function of many factors,
including the size of the patient population, the nature of the trial protocol, the proximity of
patients to clinical sites, the availability of effective treatments for the relevant disease, the
conduct of other clinical trials that compete for the same patients as our clinical trials, and the
eligibility criteria for our clinical trials. Our failure to enroll patients in our clinical trials
could delay the completion of the clinical trial beyond our expectations. In addition, the FDA
could require us to conduct clinical trials with a larger number of subjects than we have projected
for any of our product candidates. We may not be able to enroll a sufficient number of patients in
a timely or cost-effective manner. Furthermore, enrolled patients may drop out of our clinical
trials, which could impair the validity or statistical significance of the clinical trials.
We do not know whether our clinical trials will begin as planned, will need to be restructured, or
will be completed on schedule, if at all. Delays in our clinical trials will result in increased
development costs for our product candidates. In addition, if our clinical trials are delayed, our
competitors may be able to bring products to market before we do and the commercial viability of
our product candidates could be limited.
Our product candidates will remain subject to ongoing regulatory review even if they receive
marketing approval, and if we fail to comply with continuing regulations, we could lose these
approvals and the sale of any approved commercial products could be suspended.
Even if we receive regulatory approval to market a particular product candidate, the manufacturing,
labeling, packaging, adverse event reporting, storage, advertising, promotion, and record keeping
related to the product will remain subject to extensive regulatory requirements. If we fail to
comply with the regulatory requirements of the FDA and other applicable domestic and foreign
regulatory authorities or previously unknown problems with any approved product, manufacturer, or
manufacturing process is discovered, we could be subject to administrative or judicially imposed
sanctions, including:
| • | restrictions on the products, manufacturers, or manufacturing processes; | |
| • | warning letters; | |
| • | civil or criminal penalties; |
S-14
Table of Contents
| • | fines; | |
| • | injunctions; | |
| • | product seizures or detentions; | |
| • | pressure to initiate voluntary product recalls; | |
| • | suspension or withdrawal of regulatory approvals; and | |
| • | refusal to approve pending applications for marketing approval of new products or supplements to approved applications. |
If physicians and patients do not accept our future products or if the markets for indications for
which any product candidate is approved is smaller than expected, we may be unable to generate
significant revenue, if any.
Even if any of our product candidates obtain regulatory approval, they may not gain market
acceptance among physicians, patients, and third-party payors. Physicians may decide to not
recommend these drugs for a variety of reasons including:
| • | timing of market introduction of competitive products; | |
| • | demonstration of clinical safety and efficacy compared to other products; | |
| • | cost-effectiveness; | |
| • | limited or no coverage by third- party payors; | |
| • | convenience and ease of administration; | |
| • | prevalence and severity of adverse side effects; | |
| • | restrictions in the label of the drug; | |
| • | other potential advantages of alternative treatment methods; and | |
| • | ineffective marketing and distribution support of our products. |
If any approved drugs fail to achieve market acceptance, we may not be able to generate significant
revenue and our business would suffer.
We face the potential delisting of our common stock from The NASDAQ Capital Market due to the
uncertainty of our ability to timely achieve compliance with NASDAQ’s independent director and
audit committee requirements. If we are unable to meet these requirements, we could be required to
list our common stock in the over-the-counter market, which could make obtaining future financing
more difficult.
On April 6, 2011, we received written notification from NASDAQ that, as a result of Roy H.
Fickling’s resignation from our board of directors, we no longer comply with NASDAQ’s independent
director and audit committee requirements as set forth in NASDAQ Listing Rules 5605(b)(1) and
5605(c)(2), respectively. The NASDAQ Listing Rules require that a majority of our board of
directors be composed of independent directors and that the audit committee of the board of
directors be composed of at least three independent directors. Pursuant to NASDAQ Listing Rules
5605(b)(1)(A) and 5605(c)(4), we have been provided with a cure period in order to regain
compliance as follows: until the earlier of our next annual shareholders’ meeting or March 31,
2012; or if the next annual shareholders’ meeting is held before September 27, 2011, then we must
evidence compliance no later than September 27, 2011. The nominating and governance committee of
our board is currently evaluating potential candidates to fill the vacancy on our board of
directors and is assessing the composition of its audit committee.
We cannot be sure that we will be able to timely regain compliance with The NASDAQ Stock Market’s
requirements for continued listing. Neither can we be sure that we will comply with the
requirements for continued listing of our common shares on The NASDAQ Capital Market in the future.
If our common shares lose their status on The NASDAQ Capital Market, our common shares would likely
trade in the over-the-counter market.
If our shares were to trade on the over-the-counter market, selling our common shares could be more
difficult because smaller quantities of shares would likely be bought and sold, transactions could
be delayed, and security analysts’ coverage of us may be reduced. In addition, in the event our
common shares are delisted, broker-dealers have certain regulatory burdens imposed upon them, which
may discourage broker-dealers from effecting transactions in our common shares, further limiting
the liquidity of our common shares. These factors could result in lower prices and larger spreads
in the bid and ask prices for common shares.
Such delisting from The NASDAQ Capital Market and continued or further declines in our share price
and market value could also greatly impair our ability to raise additional necessary capital
through equity or debt financing, and could significantly increase the ownership dilution to
shareholders caused by our issuing equity in financing or other transactions.
We have no manufacturing capacity, and have relied and expect to continue to rely on third-party
manufacturers to produce our product candidates.
We do not own or operate manufacturing facilities for the production of clinical or commercial
quantities of our product candidates or any of the compounds that we are testing in our preclinical
programs, and we lack the resources and the capabilities to do so. As a result, we currently rely,
and we expect to rely in the future, on third-party manufacturers to supply our product candidates.
Reliance on third-party manufacturers entails risks to which we would not be subject if we
manufactured our product candidates or products ourselves, including:
| • | reliance on the third party for manufacturing process development, regulatory compliance and quality assurance; | |
| • | limitations on supply availability resulting from capacity and scheduling constraints of the third party; | |
| • | the possible breach of the manufacturing agreement by the third party because of factors beyond our control; and | |
| • | the possible termination or non-renewal of the agreement by the third party, based on our own business priorities, at a time that is costly or inconvenient for us. |
If we do not maintain our developed important manufacturing relationships, we may fail to find
replacement manufacturers or develop our own manufacturing capabilities which could delay or impair
our ability to obtain regulatory approval for our products and substantially increase our costs or
deplete profit margins, if any. If we do find replacement manufacturers, we may not be able to
enter
S-15
Table of Contents
into agreements with them on terms and conditions favorable to us, and there could be a
substantial delay before new facilities could be qualified and registered with the FDA and foreign
regulatory authorities.
The FDA and foreign regulatory authorities require manufacturers to register manufacturing
facilities. The FDA and corresponding foreign regulators also inspect these facilities to confirm
compliance with current good manufacturing practices, or cGMPs. Contract manufacturers may face
manufacturing or quality control problems causing drug substance production and shipment delays or
a situation where the contractor may not be able to maintain compliance with the applicable cGMP
requirements. Any failure to comply with cGMP requirements or other FDA and comparable foreign
regulatory requirements could adversely affect our clinical research activities and our ability to
develop our product candidates and market our products after approval.
Our current and anticipated future dependence upon others for the manufacture of our product
candidates may adversely affect our future profit margins and our ability to develop our product
candidates and commercialize any products that receive regulatory approval on a timely basis.
The uncertainty associated with pharmaceutical reimbursement and related matters may adversely
affect our business.
Upon the marketing approval of any one or more of our products, if at all, sales of our products
will depend significantly on the extent to which reimbursement for our products and related
treatments will be available from government health programs, private health insurers and other
third-party payers. Third-party payers and governmental health programs are increasingly attempting
to limit and/or regulate the price of medical products and services. The MMA, as well as other
changes in governmental or in private third-party payers’ reimbursement policies, may reduce or
eliminate any currently expected reimbursement. Decreases in third-party reimbursement for our
products could reduce physician usage of the product and have a material adverse effect on our
product sales, results of operations and financial condition. On February 17, 2009, President Obama
signed into law the American Recovery and Reinvestment Act of 2009. This law provides funding for
the federal government to compare the effectiveness of different treatments for the same illness. A
plan for the research will be developed by the Department of Health and Human Services, the Agency
for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on
the status of the research and related expenditures will be made to Congress. Although the results
of the comparative effectiveness studies are not intended to mandate any policies for public or
private payers, it is not clear what, if any, effect the research will have on the sales of our
products if any such product or the condition that it is intended to treat is the subject of a
study. Decreases in third-party reimbursement for our products or a decision by a third-party payer
to not cover our products could reduce physician usage of the product and have a material adverse
effect on our product sales, results of operations and financial condition.
The Patient Protection and Affordable Care Act and the Health Care and Education Affordability
Reconciliation Act of 2010 (collectively, the Affordable Care Act or the ACA) enacted in March
2010, are expected to have a significant impact on the health care industry. ACA is expected to
expand coverage for the uninsured while at the same time contain overall healthcare costs. With
regard to pharmaceutical products, among other things, ACA is expected to expand and increase
industry rebates for drugs covered under Medicaid programs and make changes to the coverage
requirements under the Medicare D program. We cannot predict the impact of ACA on the
pharmaceutical companies as many of the ACA reforms require the promulgation of detailed
regulations implementing the statutory provisions which has not yet occurred. In addition, the
current legal challenges to ACA, as well as congressional efforts to repeal ACA, add to the
uncertainty of the legislative changes enacted as part of ACA.
Our restated certificate of incorporation, our amended and restated by-laws, our stockholder rights
agreement and Delaware law could deter a change of our management which could discourage or delay
offers to acquire us.
Certain provisions of Delaware law and of our restated certificate of incorporation, as amended,
and amended and restated by-laws could discourage or make it more difficult to accomplish a proxy
contest or other change in our management or the acquisition of control by a holder of a
substantial amount of our voting stock. It is possible that these provisions could make it more
difficult to accomplish, or could deter, transactions that stockholders may otherwise consider to
be in their best interests or the best interests of us. Further, the rights issued under the
stockholder rights agreement would cause substantial dilution to a person or group that attempts to
acquire us on terms not approved in advance by our Board of Directors.
The price of our common stock is volatile, and is likely to continue to fluctuate due to reasons
beyond our control.
The market price of our common stock has been, and likely will continue to be highly volatile.
Factors, including our financial results or our competitors’ financial results, clinical trial and
research development announcements and government regulatory action affecting our potential
products in both the United States and foreign countries, have had, and may continue to have, a
significant effect on our results of operations and on the market price of our common stock. We
cannot assure you that your investment in our common stock will not fluctuate significantly. One or
more of these factors could significantly harm our business and cause a decline in the price of our
common stock in the public market. Substantially all of the shares of our common stock issuable
upon exercise of outstanding options and warrants have been registered for resale or are available
for sale pursuant to Rule 144 under the Securities Act
S-16
Table of Contents
of 1933, as amended, and may be sold from
time to time hereafter. Such sales, as well as future sales of our common stock by existing
stockholders, or the perception that sales could occur, could adversely affect the market price of
our common stock.
You will experience immediate dilution in the book value per share of the common stock you
purchase.
Because the price per share of our common stock being offered is substantially higher than the
book value per share of our common stock, you will suffer substantial dilution in the net tangible
book value of the common stock you purchase in this offering. If you purchase shares of common
stock in this offering, you will suffer immediate and substantial
dilution of $1.32 per share in
the net tangible book value of the common stock, assuming the sale of the entire amount offered
through this Supplemental Prospectus. See “Dilution” at page S-20 for a more detailed discussion of
the dilution you will incur in this offering.
Risks Related to This Offering
Management will have broad discretion as to the use of the proceeds from this offering, and we may
not use the proceeds effectively.
Our management will have broad discretion as to the application of the net proceeds and could use
them for purposes other than those contemplated at the time of this offering. Our stockholders may
not agree with the manner in which our management chooses to allocate and spend the net proceeds.
Moreover, our management may use the net proceeds for corporate purposes that may not increase our
profitability or our market value.
S-17
Table of Contents
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
The SEC encourages companies to disclose forward-looking information so that investors can better
understand a company’s future prospects and make informed investment decisions. This prospectus
contains such “forward-looking statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements may be made directly in this prospectus, and they may also be
made a part of this prospectus by reference to other documents filed with the SEC, which is known
as “incorporation by reference.”
Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,”
“believes” and words and terms of similar substance used in connection with any discussion of
future operating or financial performance identify forward-looking statements. All forward-looking
statements are management’s present expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ materially from those described
in the forward-looking statements. Forward-looking statements might include one or more of the
following:
| • | the initiation, timing, progress and results of our preclinical and clinical trials, research and development programs; | |
| • | the further preclinical or clinical development and commercialization of our product candidates; | |
| • | the potential benefits of our product candidates over other therapies; | |
| • | the timing, costs and other limitations involved in obtaining regulatory approval for any product; | |
| • | our ability to enter into any collaboration with respect to product candidates; | |
| • | our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; | |
| • | our ability to retain the services of our current executive officers, directors and principal consultants; | |
| • | our estimates of future performance; and | |
| • | our estimates regarding anticipated operating losses, future revenue, expenses, capital requirements and our needs for additional financing. |
These statements are only predictions and involve known and unknown risks, uncertainties and other
factors, including the risks outlined under “Risk Factors” beginning on page S-9 of this prospectus
supplement and page 6 of the accompanying prospectus, that may cause our or our industry’s actual
results, levels of activity, performance or achievements to differ from those expressed or implied
by such forward-looking statements. Before deciding to purchase our securities, you should
carefully consider the risks described in the “Risk Factors” section of this prospectus supplement,
in addition to the other information set forth in this prospectus supplement, the accompanying
prospectus and in the documents incorporated by reference herein and therein.
Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
Except as may be required by law, we do not intend to update any of the forward-looking statements
for any reason after the date of this prospectus supplement to conform such statement to actual
results or if new information becomes available.
All forward-looking statements attributable to us, or to persons acting on our behalf, are
expressly qualified in their entirety by these cautionary statements.
S-18
Table of Contents
USE OF PROCEEDS
We estimate that the maximum potential net proceeds we will receive from this offering will be
approximately $2,900,000, after deducting the agent’s fees and estimated offering expenses.
However, we cannot guarantee if or when these net proceeds will be received.
We currently intend to use the net proceeds from this offering to continue funding our internal
research and development programs, preclinical studies and clinical trials with respect to our VDA
drug candidates and general corporate purposes. We cannot estimate precisely the allocation of the
net proceeds from this offering among these uses.
We will require substantial additional funds to complete development of any product candidates.
Based on current plans, we expect that our existing resources will
fund our operations through the third quarter of fiscal 2012. Together with the expected net proceeds from this offering, we expect
that our resources will be sufficient to fund our operations through
the end of fiscal 2012, assuming the maximum potential net proceeds are received prior to the end of the third quarter of fiscal 2012. Our management will have broad discretion to allocate the net proceeds from
this offering. Pending application of the net proceeds as described above, we intend to invest the
net proceeds of the offering in investment-grade, interest-bearing securities.
Our business and an investment in our securities involve significant risks. These risks are
described under the caption “Risk Factors” beginning on page S-9 of this prospectus supplement and
page 6 of the accompanying prospectus. You should carefully consider these risk factors before
making an investment decision.
DIVIDEND POLICY
We have never declared or paid any cash dividends on our capital stock. We intend to retain any
future earnings to finance the growth and development of our business and do not anticipate paying
any cash dividends in the foreseeable future.
S-19
Table of Contents
DILUTION
If you purchase our common stock sold in this offering, your interest will be diluted to the extent
of the difference between the price per share that you pay and the net tangible book value per
share of our common stock after this offering. We calculate net tangible book value per share by
dividing the net tangible book value, tangible assets less total liabilities, by the number of
outstanding shares of our common stock.
Our net tangible book value at March 31, 2011, was approximately $686,000, or $0.09 per share,
based on 7,743,410 shares of our common stock outstanding at that date. After giving effect to the
sale of 5,583,874 shares of common stock by us during the period from April 1 through July 7, 2011
at an average public offering price of $2.38 per share (pursuant to the At Market Issuance Sales
Agreement entered into between us and our sales agent on July 21, 2010) less the agent’s fees and
our estimated offering expenses, our net tangible book value at March 31, 2011, would have been
approximately $13,260,000 or $0.99 per share. After giving effect to the assumed sale of 1,275,720
shares of common stock by us pursuant to this offering at an assumed average public offering price
of $2.43 per share (based on the closing price of our common stock on July 7, 2011), less the
agent’s fees and our estimated offering expenses, our net tangible book value at March 31, 2011,
after giving effect to the sale of 5,583,874 shares of common stock by us during the period from
April 1 through July 7, 2011 at an average public offering price of $2.38 per share, less the
agent’s fees and our estimated offering expenses, would have been approximately $16,172,000 or
$1.11 per share. This represents an immediate increase in the net tangible book value of $0.12 per
share to existing stockholders and an immediate dilution of $1.32 per share to investors in this
offering. The following table illustrates this estimated per share dilution:
Assumed average public offering price per share (based on the closing
price of our common stock on July 7, 2011) |
$ | 2.43 | ||
Net tangible book value per share as of March 31, 2011* |
$ | 0.99 | ||
Increase in net tangible book value per share attributable to the offering* |
$ | 0.12 | ||
Net tangible book value per share after the offering* |
$ | 1.11 | ||
Dilution per share to new investors* |
$ | 1.32 |
| * | After giving effect to the sale of 5,583,874 shares of common stock by us during the period from April 1 through July 7, 2011 at an average public offering price of $2.38 per share, less the agent’s fees and our estimated offering expenses. |
In the discussion and table above, we assume no exercise of outstanding options or warrants. As of
July 7, 2011, there were 306,674 shares of common stock reserved for issuance upon exercise of
outstanding options with a weighted average exercise price of $29.15 per share. In addition, as of
July 7, 2011, there were:
| • | 12,500 shares of common stock issuable upon the exercise of warrants issued in February 2008 at a weighted average exercise price of $54.80 per share; | |
| • | 140,625 shares of common stock issuable upon the exercise of the five-year warrants issued in July 2009 at an exercise price of $42.00 per share; and | |
| • | 180,012 shares of common stock reserved for future awards under our stock plan and employee stock purchase plan. |
S-20
Table of Contents
PLAN OF DISTRIBUTION
We have entered into a sales agreement, dated July 21, 2010 with McNicoll, Lewis & Vlak LLC
(“MLV”), under which we may sell our common stock from time to time through MLV, as our agent for
the offer and sale of the common stock. Based on the trading price of our common stock, we may not
be able to raise the full $3,100,000 in gross proceeds contemplated by this prospectus supplement.
MLV may sell the common stock by any method permitted by law, including sales deemed to be an “at
the market” offering as defined in Rule 415 of the Securities Act, including without limitation
sales made directly on The NASDAQ Capital Market, on any other existing trading market for the
common stock or to or through a market maker. MLV may also sell the common stock in privately
negotiated transactions, subject to our prior approval.
Each time that we wish to issue and sell common stock under the sales agreement, we will provide
MLV with a placement notice describing the number of shares to be issued, the time period during
which sales are requested to be made, any limitation on the number of shares of common stock that
may be sold in any one day and any minimum price below which sales may not be made.
Upon receipt of a placement notice from us, and subject to the terms and conditions of the sales
agreement, MLV has agreed to use its commercially reasonable efforts consistent with its normal
trading and sales practices to sell such shares up to the amount specified on such terms. The
settlement between us and MLV of our common stock will occur on the third trading day following the
date on which the sale was made. The obligation of MLV under the sales agreement to sell our common
stock pursuant to a placement notice is subject to a number of conditions.
We will
pay MLV a commission up to 5% of the gross proceeds of the sales price for all shares of
common stock sold through it as sales agent under the sales agreement. Based on the trading price
of our common stock, we may not be able to raise the full $3,100,000 in gross proceeds contemplated
by this prospectus supplement. Because there is no minimum offering amount provided for under the
sales agreement, the actual total may be less than the maximum amount set forth above.
In connection with the sale of our common stock contemplated by this prospectus supplement, MLV
will be deemed to be an “underwriter” within the meaning of the Securities Act of 1933, as amended,
and the compensation paid to MLV will be deemed to be underwriting commissions or discounts. We
have agreed to indemnify MLV against certain civil liabilities, including liabilities under the
Securities Act of 1933.
Sales of our common stock as contemplated in this prospectus will be settled through the facilities
of The Depository Trust Company or by such other means as we and MLV may agree upon.
The offering of our common stock pursuant to the sales agreement will terminate on the earliest of
(1) the sale of all of our common stock subject to each sales agreement, or (2) termination of the
sales agreement by us or MLV, as permitted therein. MLV may terminate the sales agreement at any
time in certain circumstances, including the occurrence of a material adverse change that, in MLV’s
reasonable judgment, may impair its ability to sell the common stock, our failure to satisfy any
condition under of the sales agreement or a suspension or limitation of trading of our common stock
on NASDAQ. We may terminate the sales agreement at any time upon 30 days’ prior notice, and MLV may
terminate the sales agreement at any time upon 60 days’ prior notice.
This is a brief summary of the material provisions of the sales agreement and does not purport to
be a complete statement of its terms and conditions. A copy of the sales agreement is filed with
the SEC and incorporated by reference into the registration statement of which this prospectus
forms a part. See “Where You Can Find More Information” on page 19 of the accompanying prospectus.
The At Market Issuance Sales Agreement is included as an exhibit to our Current Report on Form 8-K
that we filed with the Commission on July 21, 2010 in connection with this offering. We have filed
separate prospectus supplements, dated July 21, 2010,
January 31, 2011, June 1, 2011 and June 29, 2011, relating
to sales of shares of our common stock pursuant to the At Market Issuance Sales Agreement. This
prospectus supplement relates to additional potential sales of our common stock pursuant to that
same agreement.
The transfer agent for our common stock to be issued in this offering is American Stock Transfer &
Trust Company, LLC.
Our common stock is traded on The NASDAQ Capital Market under the symbol “OXGN.”
MLV, formed in July 2009 and registered as a broker-dealer in January 2010, is an independent full
service investment bank and institutional broker dealer located in New York. Its banking and
research divisions focus on the energy, infrastructure, healthcare, and life sciences sectors. It
has served as agent or co-agent for over 25 publicly filed at-the-market offerings of equity
securities since registering as a broker-dealer. MLV has no relationship with the Company other
than its current role as a sales agent for the Company’s at-the-market offerings of common stock.
LEGAL MATTERS
The validity of the securities we are offering will be passed upon for us by Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., Boston, Massachusetts. MLV is being represented in connection with
this offering by Holme Roberts & Owen LLP, Denver, Colorado.
S-21
Table of Contents
EXPERTS
The consolidated financial statements of OXiGENE, Inc. appearing in OXiGENE, Inc.’s Annual Report
(Form 10-K) for the year ended December 31, 2010 have been audited by Ernst & Young LLP,
independent registered public accounting firm, as set forth in their report thereon (which contains
an explanatory paragraph describing conditions that raise substantial doubt about the Company’s
ability to continue as a going concern as described in Note 1 to the consolidated financial
statements), included therein, and incorporated herein by reference. Such consolidated financial
statements are incorporated herein by reference in reliance upon such report given on the authority
of such firm as experts in accounting and auditing.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” the information we file with it, which means that
we can disclose important information to you by referring you to those documents. The information
incorporated by reference is considered to be part of this prospectus and information we file later
with the SEC will automatically update and supersede this information. We incorporate by reference
into this prospectus supplement and the accompanying prospectus the documents listed below and any
future filings made by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
after the date of this prospectus supplement and prior to the time that we sell all of the
securities offered by this prospectus supplement or the earlier termination of the offering (except
in each case the information contained in such documents to the extent “furnished” and not
“filed”). The documents we are incorporating by reference as of their respective dates of filing
are:
S-22
Table of Contents
| • | Our Annual Report on Form 10-K for the year ended December 31, 2010, filed on March 16, 2011 (File No. 000-21990); | ||
| • | Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2010, filed on May 2, 2011 (File No. 000-21990); | ||
| • | Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, filed on May 13, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on January 19, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on January 25, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on January 31, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on February 22, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on March 2, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on March 16, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on March 21, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on March 23, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on April 6, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on April 7, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on May 12, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on June 1, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on June 6, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on June 6, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on June 6, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on June 21, 2011 (File No. 000-21990); | ||
| • | Our Current Report on Form 8-K filed on June 29, 2011 (File No. 000-21990); | ||
| • | The description of our common stock contained in our Registration Statement on Form 8-A filed on June 24, 1993 (File No. 0-21990) pursuant to Section 12(g) of the Exchange Act, which incorporates by reference the description of the shares of our common stock contained in our Registration Statement on Form S-1 (File No. 33-64968) filed on June 24, 1993 and declared effective by the SEC on August 25, 1993, and any amendment or report filed with the SEC for purposes of updating such description; and | ||
| • | The description of the Rights under the Stockholder Rights Agreement (which are currently transferred with our common stock) contained in our Registration Statement on Form 8-A12G (File No. 000-21990) filed under the Exchange Act with the Commission on March 30, 2005, including any amendment or report filed for the purpose of updating such description. |
Any statement contained in this prospectus or in a document incorporated or deemed to be
incorporated by reference into this prospectus supplement will be deemed to be modified or
superseded for purposes of this prospectus supplement to the extent that a statement contained in
this prospectus supplement or any other subsequently filed document that is deemed to be
incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any
statement so modified or superseded will not be deemed, except as so modified or superseded, to
constitute a part of this prospectus supplement.
S-23
Table of Contents
You may request, orally or in writing, a copy of these documents, which will be provided to you at
no cost, by contacting OXiGENE, Inc., 701 Gateway Boulevard, Suite 210, South San Francisco,
California 94080, Attention: Investor Relations. The Investor Relations Department can be reached
via telephone at (650) 635-7000.
S-24
Table of Contents
PROSPECTUS
OXiGENE, INC.
$50,000,000
COMMON STOCK
DEBT SECURITIES
WARRANTS
We may from time to time issue up to $50,000,000 aggregate
principal amount of common stock, debt securities
and/or
warrants. We will specify in an accompanying prospectus
supplement the terms of the securities. We may issue or sell
these securities to or through underwriters, directly to
purchasers, or through agents. We will set forth the names of
any underwriters or agents in the accompanying prospectus
supplement.
Our common stock is listed on the NASDAQ Global Market under the
symbol “OXGN.” The market value of our outstanding
common equity held by non-affiliates on October 31, 2008
was approximately $22,724,000, based on 35,011,448 shares
of outstanding common stock, of which 7,632,588 are held by
non-affiliates, and a per share price of $0.83 based on the
closing sale price of our common stock on October 31, 2008.
We have not offered any securities pursuant to General
Instruction I.B.6 of
Form S-3
during the 12 calendar months prior to and including the date
hereof.
Investing in our securities involves risks. See “Risk
Factors” on page 6.
Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this
prospectus. Any representation to the contrary is a criminal
offense.
This prospectus may not be used to consummate sales of
securities unless it is accompanied by a prospectus supplement.
The date of this prospectus is December 1, 2008.
Table of Contents
TABLE OF
CONTENTS
| Page | ||||
| 3 | ||||
| 3 | ||||
| 6 | ||||
| 6 | ||||
| 6 | ||||
| 7 | ||||
| 7 | ||||
| 8 | ||||
| 13 | ||||
| 15 | ||||
| 17 | ||||
| 18 | ||||
| 18 | ||||
| 19 | ||||
| 19 | ||||
2
Table of Contents
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement that we
filed with the Securities and Exchange Commission, or SEC,
utilizing a “shelf” registration process. Under this
shelf process, we may sell any combination of the securities
described in this prospectus in one or more offerings up to a
total dollar amount of $50,000,000. We have provided to you in
this prospectus a general description of the securities we may
offer. Each time we sell securities, we will provide a
prospectus supplement that will contain specific information
about the terms of that offering. In any applicable prospectus
supplements, we may add to, update or change any of the
information contained in this prospectus.
OUR
BUSINESS
The following is only a summary. We urge you to read the entire
prospectus, including the more detailed financial statements,
notes to the financial statements and other information
incorporated by reference from our other filings with the
U.S. Securities and Exchange Commission (SEC). Investing in
our securities involves risk. Accordingly, please carefully
consider the information provided under the heading “Risk
Factors” on page 6.
Our
Business
OXiGENE, Inc. (“OXiGENE” or the “Company”)
is a clinical-stage, biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The
Company’s primary focus is the development and
commercialization of product candidates referred to as
vascular disrupting agents (VDAs) that selectively
disrupt abnormal blood vessels associated with solid tumor
progression and visual impairment in a number of ocular diseases
which are characterized by abnormal blood vessel growth. Because
its VDA product candidates act via a validated therapeutic
mechanism, inhibition of blood flow to tumors and neovascular
lesions within the eye, the Company believes the risk associated
with its drug development programs is relatively low compared to
compounds with unvalidated or unknown mechanisms of action.
OXiGENE’s most advanced therapeutic product candidate,
ZYBRESTATtm
(generic name fosbretabulin, previously known as combretastatin
A4 phosphate or CA4P), is currently being evaluated in a Phase
II/III pivotal registration study as a potential treatment for
anaplastic thyroid cancer, a highly aggressive and lethal
malignancy for which there are currently no approved
therapeutics and extremely limited treatment options. In
addition, ZYBRESTAT is being evaluated in Phase II clinical
trials as a potential treatment for: (i) non-small cell
lung cancer (NSCLC) in combination with the chemotherapeutic
agents, carboplatin and paclitaxel, and the anti-angiogenic
agent, bevacizumab; and (ii) platinum resistant ovarian
cancer in combination with carboplatin and paclitaxel. The
Company believes that these trials, if successful, will
establish a compelling rationale for further development of
ZYBRESTAT as a treatment (i) for other forms of recurrent,
metastatic thyroid cancer; (ii) for other aggressive and
difficult-to-treat
malignancies; (iii) for use in combination with
chemotherapy in a variety of solid tumors in which carboplatin
and paclitaxel chemotherapy are commonly used; and (iv) for
use in combination with anti-angiogenic agents in other solid
tumors in which anti-angiogenic therapies are commonly used. The
Company believes these areas for potential further development
collectively represent a very large potential commercial market
opportunity. In addition, based upon preclinical results first
published by its collaborators in the November 2007 online issue
of the journal Blood, OXiGENE believes that ZYBRESTAT and
its other VDA product candidates may also have utility in the
treatment of hematological malignancies or “liquid
tumors.” Approximately 350 subjects have been treated to
date with ZYBRESTAT in human clinical trials. In light of the
significant human clinical experience with ZYBRESTAT to date,
and because ZYBRESTAT acts via a validated therapeutic
mechanism, inhibition of tumor blood-flow, the Company believes
that the development risks associated with ZYBRESTAT are
relatively low compared to compounds with unvalidated or unknown
mechanisms of action.
In addition to developing ZYBRESTAT as an intravenously
administered therapy for cancer indications, OXiGENE is
developing a topical formulation of ZYBRESTAT for
ophthalmological diseases and conditions, such as age-related
macular degeneration (AMD) that are characterized by abnormal
blood vessel growth within the eye that results in loss of
vision. The Company believes that a safe, effective, convenient
topically-
3
Table of Contents
administered anti-vascular therapeutic would have advantages
over currently-approved anti-vascular, ophthalmological
therapeutics, which must be injected directly into
patients’ eyes on a frequent basis. In addition to having
potential utility for treating ocular diseases and conditions
such as AMD that affect tissues such as the choroid in the back
of the eye, the Company believes that a topical ophthalmological
formulation of ZYBRESTAT could also have utility for the
treatment of other ocular diseases and conditions that affect
tissues in the front of the eye, such as the cornea and iris,
which are characterized by abnormal growth of blood vessels, or
neovascularization. The Company currently plans to undertake a
series of preclinical studies and clinical trials with the
objective of demonstrating the utility of a topical formulation
of ZYBRESTAT in an ophthalmologic indication.
OXiGENE is currently evaluating a second-generation VDA product
candidate, OXi4503, in a Phase I clinical trial in patients with
advanced solid tumors. The Company refers to OXi4503 as an
ortho-quinone prodrug (OQP). In preclinical studies, OXi4503 has
shown potent anti-tumor activity, both as a single-agent and in
combination with other cancer treatment modalities. The Company
believes that OXi4503 is differentiated from other VDAs by its
ability to exert (i) potent vascular disrupting effects on
tumor vasculature; and (ii) direct cytotoxic effects on
tumor cells. OXi4503 is currently in a Phase I clinical trial in
patients with advanced solid tumors. Based on favorable results
in preclinical studies, the Company currently plans to undertake
further clinical trials with OXi4503 in acute myeloid leukemia
(AML) and hepatic tumors.
As described below under “— Symphony
Transaction,” ZYBRESTAT for use in ophthalmologic
indications and OXi4503 were exclusively licensed to Symphony
ViDA, Inc. under the Novated and Restated Technology License
Agreement on October 1, 2008.
Finally, under a sponsored research agreement with Baylor
University, the Company is pursuing discovery and development of
novel, small-molecule therapeutics for the treatment of cancer
that it believes will be complementary with its later-stage VDA
product candidates.
Symphony
Transaction
On October 1, 2008, OXiGENE entered into a series of
related agreements with Symphony Capital LLC, or Symphony,
Symphony ViDA, Inc., or ViDA, Symphony ViDA Holdings LLC, or
Holdings, and related entities, including the following:
| • | Purchase Option Agreement; | |
| • | Research and Development Agreement; | |
| • | Amended and Restated Research and Development Agreement; | |
| • | Technology License Agreement; | |
| • | Novated and Restated Technology License Agreement; | |
| • | Confidentiality Agreement; and | |
| • | Additional Funding Agreement. |
In addition, on October 1, 2008, OXiGENE entered into a
series of related agreements with Holdings, including the
following:
| • | Stock and Warrant Purchase Agreement; | |
| • | Warrant to purchase up to 11,281,877 shares of OXiGENE common stock; and | |
| • | Registration Rights Agreement. |
Pursuant to these agreements, Holdings has formed and
capitalized ViDA, a newly formed Delaware corporation, in order
(a) to hold certain intellectual property related to two of
OXiGENE’s product candidates, ZYBRESTAT for use in
ophthalmologic indications and OXi4503, referred to as the
“Programs,” which were exclusively licensed to ViDA
under the Novated and Restated Technology License Agreement and
(b) to fund commitments in the amount of up to
$25 million. The funding will support preclinical and
clinical
4
Table of Contents
development by OXiGENE, on behalf of ViDA, of the Programs.
Under certain circumstances, the Company may be required to
commit up to $15 million to ViDA. The Company is developing
a topical formulation of ZYBRESTAT for ophthalmologic diseases
and conditions, such as age-related macular degeneration, that
are characterized by abnormal blood vessel growth within the eye
that results in loss of vision. The Company currently plans to
undertake a series of preclinical and clinical studies with the
objective of demonstrating the utility of a topical formulation
of ZYBRESTAT in an ophthalmologic indication. OXi4503 is
currently in a Phase I clinical trial in patients with advanced
solid tumors. Based on favorable results in preclinical studies,
the Company currently plans to undertake further clinical trials
with OXi4503 in AML and hepatic tumors.
The Purchase Option Agreement provides for the exclusive right,
but not the obligation, of OXiGENE to repurchase both Programs
by acquiring 100% of the equity of ViDA at any time between
October 2, 2009 and March 31, 2012 for an amount equal
to two times the amount of capital actually invested by Holdings
in ViDA, less certain amounts. The purchase price is payable in
cash or a combination of cash and shares of OXiGENE common stock
(up to 20% of the purchase price or 10% of the total number of
shares of OXiGENE common stock outstanding at such time,
whichever is less), in OXiGENE’s sole discretion, subject
to certain limitations. If OXiGENE does not exercise its
exclusive right with respect to the purchase of the Programs
licensed under the agreement with ViDA, rights to the Programs
at the end of the development period will remain with ViDA.
OXiGENE has issued to Holdings, pursuant to the Stock and
Warrant Purchase Agreement, (1) an aggregate of
5,835,241 shares of OXiGENE common stock (the
“Shares”), and (2) a ten-year warrant to purchase
11,281,877 shares of OXiGENE common stock (the
“Warrant”) at an exercise price of $1.11 per share,
the closing price of OXiGENE common stock on The NASDAQ Global
Market on September 30, 2008, the day before the
consummation of the Symphony transaction. OXiGENE may issue
additional shares of its common stock and warrants in the event
of specified events under the Additional Funding Agreement, the
Novated and Restated Technology License Agreement and the
Purchase Option Agreement. OXiGENE has agreed to provide certain
registration rights under the Securities Act of 1933, as amended
(the “Securities Act”) with respect to the shares
issued and to be issued to Holdings under these agreements.
The Amended and Restated Research and Development Agreement
provides that the conduct of the activities under the mutually
agreed upon development plan and budget during the development
period will be undertaken primarily by OXiGENE with support from
RRD International LLC, the clinical development partner of
Symphony, and provides that the development will be overseen by
a Development Committee which is comprised of six
representatives, three representatives to be designated by
OXiGENE, one of which shall be Patricia A.
Walicke, M.D., Ph.D., OXiGENE’s Vice President
and Chief Medical Officer, who shall serve as chairman of the
Development Committee, and three representatives to be
designated by Holdings. The Development Committee will report to
the board of directors of ViDA, which will be comprised of
John Kollins, OXiGENE’s Chief Executive Officer, two
representatives of Symphony, Mark Kessel and Jeffrey S. Edelman,
and two independent board members.
In addition, OXiGENE has given Holdings the right to appoint two
members to its Board of Directors. Holdings has designated Mark
Kessel and Alastair J.J. Wood, M.D., both Managing
Directors of Symphony Capital LLC, as the Holdings
representatives, who were appointed to the Board on
October 22, 2008.
Company
Background
The Company is a Delaware corporation, incorporated in 1988 in
the state of New York and reincorporated in 1992 in the state of
Delaware, with its corporate office in the United States at 230
Third Avenue, Waltham, Massachusetts 02451 (telephone:
781-547-5900;
fax:
781-547-6800).
We also have offices located at 1001 Bay Hill Drive,
San Bruno, California and in the United Kingdom at Magdalen
Centre, Robert Robinson Avenue, The Oxford Science Park,
Oxford, OX4 4GA. The Company’s Internet address is
www.OXiGENE.com. The Company’s annual reports on
Form 10-K,
quarterly reports on
Form 10-Q,
current reports on
Form 8-K,
and all amendments to those reports, are available to you free
of charge through the Investor Relations section of our web site
as soon as reasonably practicable after such materials have been
electronically filed with, or furnished to, the SEC.
5
Table of Contents
RISK
FACTORS
Investing in our securities is very risky. Please carefully
consider the risk factors described in our periodic reports
filed with the SEC, including our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007, which is
incorporated by reference into this prospectus. Before making an
investment decision, you should carefully consider these risks
as well as other information we include or incorporate by
reference into this prospectus or include in any applicable
prospectus supplement. Additional risks and uncertainties not
presently known to us or that we deem currently immaterial may
also impair our business operations. You should be able to bear
a complete loss of your investment. See “Special Note
Regarding Forward-Looking Statements.”
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
The SEC encourages companies to disclose forward-looking
information so that investors can better understand a
company’s future prospects and make informed investment
decisions. This prospectus contains such “forward-looking
statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be made
directly in this prospectus, and they may also be made a part of
this prospectus by reference to other documents filed with the
SEC, which is known as “incorporation by reference.”
Words such as “may,” “anticipate,”
“estimate,” “expects,” “projects,”
“intends,” “plans,” “believes” and
words and terms of similar substance used in connection with any
discussion of future operating or financial performance identify
forward-looking statements. All forward-looking statements are
management’s present expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Forward-looking statements might
include one or more of the following:
| • | anticipated results of financing activities; | |
| • | anticipated clinical trial timelines or results; | |
| • | anticipated research and product development results; | |
| • | projected regulatory timelines; | |
| • | descriptions of plans or objectives of management for future operations, products or services; | |
| • | forecasts of future economic performance; and | |
| • | descriptions or assumptions underlying or relating to any of the above items. |
Please also see the discussion of risks and uncertainties under
the heading “Risk Factors” in our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2007.
In light of these assumptions, risks and uncertainties, the
results and events discussed in the forward-looking statements
contained in this prospectus or in any document incorporated by
reference might not occur. Investors are cautioned not to place
undue reliance on the forward-looking statements, which speak
only as of the date of this prospectus or the date of the
document incorporated by reference into this prospectus. We are
not under any obligation, and we expressly disclaim any
obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or
otherwise. All subsequent forward-looking statements
attributable to OXiGENE or to any person acting on its behalf
are expressly qualified in their entirety by the cautionary
statements contained or referred to in this section.
USE OF
PROCEEDS
Unless we indicate otherwise in the applicable prospectus
supplement, we currently intend to use the net proceeds from
this offering for general corporate purposes, including our
internal discovery and development programs and the development
of new technologies, general working capital and possible future
acquisitions.
6
Table of Contents
We have not determined the amounts we plan to spend on any of
the areas listed above or the timing of these expenditures. As a
result, our management will have broad discretion to allocate
the net proceeds from this offering. Pending application of the
net proceeds as described above, we intend to invest the net
proceeds of the offering in short-term, investment-grade,
interest-bearing securities.
We may set forth additional information on the use of net
proceeds from the sale of securities we offer under this
prospectus in a prospectus supplement relating to the specific
offering.
THE
SECURITIES WE MAY OFFER
The descriptions of the securities contained in this prospectus,
together with the applicable prospectus supplements, summarize
all the material terms and provisions of the various types of
securities that we may offer. We will describe in the applicable
prospectus supplement relating to any securities the particular
terms of the securities offered by that prospectus supplement.
If we indicate in the applicable prospectus supplement, the
terms of the securities may differ from the terms we have
summarized below. We will also include information in the
prospectus supplement, where applicable, about material United
States federal income tax considerations relating to the
securities, and the securities exchange, if any, on which the
securities will be listed.
We may sell from time to time, in one or more offerings:
| • | common stock; | |
| • | debt securities; and/or | |
| • | warrants to purchase any of the securities listed above. |
This prospectus may not be used to consummate a sale of
securities unless it is accompanied by a prospectus supplement.
DESCRIPTION
OF COMMON STOCK
The following description of our capital stock and certain
provisions of our restated certificate of incorporation, as
amended, and our amended and restated by-laws is a summary and
is qualified in its entirety by the provisions of our restated
certificate of incorporation, as amended, and our amended and
restated by-laws.
Our authorized capital stock consists of 100,000,000 shares
of common stock, par value of $0.01 per share.
Common
Stock
We are authorized to issue 100,000,000 shares of common
stock. Each stockholder of record is entitled to one vote for
each outstanding share of our common stock owned by that
stockholder on every matter properly submitted to the
stockholders for their vote. Holders of common stock are
entitled to any dividend declared by our board out of funds
legally available for that purpose. Holders of common stock are
entitled to receive, on a pro rata basis, all our remaining
assets available for distribution to stockholders in the event
of our liquidation, dissolution or winding up. Holders of common
stock do not have any preemptive right to become subscribers or
purchasers of additional shares of any class of our capital
stock.
Listing
Our common stock is listed on the NASDAQ Global Market under the
symbol “OXGN.”
Transfer
Agent and Registrar
American Stock Transfer & Trust Company is the
transfer agent and registrar for our common stock.
7
Table of Contents
Delaware
Law, Certain Charter and By-Law Provisions and Stockholder
Rights Agreement
The provisions of Delaware law and of our restated certificate
of incorporation, as amended, and amended and restated by-laws
discussed below could discourage or make it more difficult to
accomplish a proxy contest or other change in our management or
the acquisition of control by a holder of a substantial amount
of our voting stock. It is possible that these provisions could
make it more difficult to accomplish, or could deter,
transactions that stockholders may otherwise consider to be in
their best interests or the best interests of OXiGENE.
Delaware Statutory Business Combinations
Provision. In general, Section 203 prohibits
a publicly-held Delaware corporation from engaging in a
“business combination” with an “interested
stockholder” for a period of three years after the date of
the transaction in which the person became an interested
stockholder, unless the business combination is, or the
transaction in which the person became an interested stockholder
was, approved in a prescribed manner or another prescribed
exception applies. For purposes of Section 203, a
“business combination” is defined broadly to include a
merger, asset sale or other transaction resulting in a financial
benefit to the interested stockholder, and, subject to certain
exceptions, an “interested stockholder” is a person
who, together with his or her affiliates and associates, owns
(or within the prior three years, did own) 15% or more of the
corporation’s voting stock.
Special Meetings of Stockholders. Special
meetings of the stockholders may be called by the chairman of
our board of directors, the president, or the entire board of
directors pursuant to a resolution adopted by a majority of
directors present at a meeting at which a quorum is present. The
president or Secretary shall also call special meetings upon the
written request of not less than 10% in interest of the
stockholders entitled to vote at the meeting.
Stockholder Rights Agreement. On
March 24, 2005 our Board of Directors declared a dividend
of one common stock purchase right for each outstanding share of
our voting common stock, $0.01 par value per share, to
stockholders of record at the close of business on April 4,
2005. Each right entitles the registered holder to purchase from
us one share of common stock, at a purchase price of $50.00 in
cash, subject to adjustment. The description and terms of the
rights are set forth in a Stockholder Rights Agreement, as
amended, between us and American Stock Transfer &
Trust Company, as Rights Agent.
Initially, the rights will be attached to all common stock
certificates representing shares then outstanding, and no
separate certificates for rights will be distributed. The rights
will separate from the common stock and a “Distribution
Date” will occur upon the earlier of (i) 10 days
following a public announcement that a person or group of
affiliated or associated persons has acquired, or obtained the
right to acquire, beneficial ownership of 15% or more of the
outstanding shares of our common stock or (ii) 10 business
days following the commencement of a tender offer or exchange
offer that may result in a person or group beneficially owning
15% or more of the outstanding shares of our common stock.
Until the distribution date (or earlier redemption or expiration
of the rights), (i) the rights will be evidenced by the
common stock certificates and will be transferred with and only
with such common stock certificates, (ii) new common stock
certificates issued after the record date will contain a
notation incorporating the Stockholder Rights Agreement by
reference, and (iii) the surrender for transfer of any
certificates for common stock outstanding, even without such
notation, will also constitute the transfer of the rights
associated with the common stock represented by such certificate.
DESCRIPTION
OF DEBT SECURITIES
The following description, together with the additional
information we include in any applicable prospectus supplement,
summarizes the material terms and provisions of the debt
securities that we may offer under this prospectus. While the
terms we have summarized below will apply generally to any
future debt securities we may offer, we will describe the
particular terms of any debt securities that we may offer in
more detail in the applicable prospectus supplement. If we so
indicate in a prospectus supplement, the terms of any debt
securities we offer under that prospectus supplement may differ
from the terms we describe below.
8
Table of Contents
We will issue senior notes under a senior indenture, which we
will enter into with a trustee to be named in the senior
indenture. We will issue subordinated notes under a subordinated
indenture, which we will enter into with a trustee to be named
in the subordinated indenture. We use the term
“indentures” to refer to both the senior indenture and
the subordinated indenture. The indentures will be qualified
under the Trust Indenture Act of 1939, as amended (the
“Trust Indenture Act”). We use the term
“debenture trustee” to refer to either the senior
trustee or the subordinated trustee, as applicable.
The following summaries of material provisions of the senior
notes, the subordinated notes and the indentures are subject to,
and qualified in their entirety by reference to, all the
provisions of the indenture applicable to a particular series of
debt securities. Except as we may otherwise indicate, the terms
of the senior indenture and the subordinated indenture will be
identical.
General
We will describe in each prospectus supplement the following
terms relating to a series of notes:
| • | the title; | |
| • | any limit on the amount that may be issued; | |
| • | whether or not we will issue the series of notes in global form, the terms and who the depository will be; | |
| • | the maturity date; | |
| • | the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; | |
| • | whether or not the notes will be secured or unsecured, and the terms of any secured debt; | |
| • | the terms of the subordination of any series of subordinated debt; | |
| • | the place where payments will be made; | |
| • | our right, if any, to defer payment of interest and the maximum length of any such deferral period; | |
| • | the date, if any, after which, and the price at which, we may, at our option, redeem the series of notes pursuant to any optional redemption provisions; | |
| • | the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of notes; | |
| • | whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves; | |
| • | whether we will be restricted from incurring any additional indebtedness; | |
| • | a discussion of any material or special United States federal income tax considerations applicable to the notes; | |
| • | the denominations in which we will issue the series of notes, if other than denominations of $1,000 and any integral multiple thereof; and | |
| • | any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities. |
Conversion
or Exchange Rights
We will set forth in the prospectus supplement the terms on
which a series of notes may be convertible into or exchangeable
for common stock or other securities of ours. We will include
provisions as to whether conversion or exchange is mandatory, at
the option of the holder or at our option. We may include
provisions
9
Table of Contents
pursuant to which the number of shares of common stock or other
securities of ours that the holders of the series of notes
receive would be subject to adjustment.
Consolidation,
Merger or Sale
The indentures will not contain any covenant which restricts our
ability to merge or consolidate, or sell, convey, transfer or
otherwise dispose of all or substantially all of our assets.
However, any successor to or acquirer of such assets must assume
all of our obligations under the indentures or the notes, as
appropriate.
Events of
Default Under the Indenture
The following will be events of default under the indentures
with respect to any series of notes that we may issue:
| • | if we fail to pay interest when due and our failure continues for 90 days and the time for payment has not been extended or deferred; | |
| • | if we fail to pay the principal, or premium, if any, when due and the time for payment has not been extended or delayed; | |
| • | if we fail to observe or perform any other covenant contained in the notes or the indentures, other than a covenant specifically relating to another series of notes, and our failure continues for 90 days after we receive notice from the debenture trustee or holders of at least 25% in aggregate principal amount of the outstanding notes of the applicable series; and | |
| • | if specified events of bankruptcy, insolvency or reorganization occur as to us. |
If an event of default with respect to notes of any series
occurs and is continuing, the debenture trustee or the holders
of at least 25% in aggregate principal amount of the outstanding
notes of that series, by notice to us in writing, and to the
debenture trustee if notice is given by such holders, may
declare the unpaid principal of, premium, if any, and accrued
interest, if any, due and payable immediately.
The holders of a majority in principal amount of the outstanding
notes of an affected series may waive any default or event of
default with respect to the series and its consequences, except
defaults or events of default regarding payment of principal,
premium, if any, or interest, unless we have cured the default
or event of default in accordance with the indenture. Any such
waiver shall cure the default or event of default.
Subject to the terms of the indentures, if an event of default
under an indenture shall occur and be continuing, the debenture
trustee will be under no obligation to exercise any of its
rights or powers under such indenture at the request or
direction of any of the holders of the applicable series of
notes, unless such holders have offered the debenture trustee
reasonable indemnity. The holders of a majority in principal
amount of the outstanding notes of any series will have the
right to direct the time, method and place of conducting any
proceeding for any remedy available to the debenture trustee, or
exercising any trust or power conferred on the debenture
trustee, with respect to the notes of that series, provided that:
| • | the direction so given by the holder is not in conflict with any law or the applicable indenture; and | |
| • | subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. |
A holder of the notes of any series will only have the right to
institute a proceeding under the indentures or to appoint a
receiver or trustee, or to seek other remedies if:
| • | the holder has given written notice to the debenture trustee of a continuing event of default with respect to that series; | |
| • | the holders of at least 25% in aggregate principal amount of the outstanding notes of that series have made written request, and such holders have offered reasonable indemnity, to the debenture trustee to institute the proceeding as trustee; and |
10
Table of Contents
| • | the debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding notes of that series other conflicting directions within 60 days after the notice, request and offer. |
These limitations do not apply to a suit instituted by a holder
of notes if we default in the payment of the principal, premium,
if any, or interest on, the notes.
We will periodically file statements with the debenture trustee
regarding our compliance with specified covenants in the
indentures.
Modification
of Indenture; Waiver
We and the debenture trustee may change an indenture without the
consent of any holders with respect to specific matters,
including:
| • | to fix any ambiguity, defect or inconsistency in the indenture; and | |
| • | to change anything that does not materially adversely affect the interests of any holder of notes of any series. |
In addition, under the indentures, the rights of holders of a
series of notes may be changed by us and the debenture trustee
with the written consent of the holders of at least a majority
in aggregate principal amount of the outstanding notes of each
series that is affected. However, we and the debenture trustee
may only make the following changes with the consent of each
holder of any outstanding notes affected:
| • | extending the fixed maturity of the series of notes; | |
| • | reducing the principal amount, reducing the rate of or extending the time of payment of interest, or any premium payable upon the redemption of any notes; or | |
| • | reducing the percentage of notes, the holders of which are required to consent to any amendment. |
Discharge
Each indenture provides that we can elect to be discharged from
our obligations with respect to one or more series of debt
securities, except for obligations to:
| • | register the transfer or exchange of debt securities of the series; | |
| • | replace stolen, lost or mutilated debt securities of the series; | |
| • | maintain paying agencies; | |
| • | hold monies for payment in trust; | |
| • | compensate and indemnify the trustee; and | |
| • | appoint any successor trustee. |
In order to exercise our rights to be discharged, we must
deposit with the trustee money or government obligations
sufficient to pay all the principal of, any premium, if any, and
interest on, the debt securities of the series on the dates
payments are due.
Form,
Exchange, and Transfer
We will issue the notes of each series only in fully registered
form without coupons and, unless we otherwise specify in the
applicable prospectus supplement, in denominations of $1,000 and
any integral multiple thereof. The indentures provide that we
may issue notes of a series in temporary or permanent global
form and as book-entry securities that will be deposited with,
or on behalf of, The Depository Trust Company or another
depository named by us and identified in a prospectus supplement
with respect to that series. See “Legal Ownership of
Securities” for a further description of the terms relating
to any book-entry securities.
11
Table of Contents
At the option of the holder, subject to the terms of the
indentures and the limitations applicable to global securities
described in the applicable prospectus supplement, the holder of
the notes of any series can exchange the notes for other notes
of the same series, in any authorized denomination and of like
tenor and aggregate principal amount.
Subject to the terms of the indentures and the limitations
applicable to global securities set forth in the applicable
prospectus supplement, holders of the notes may present the
notes for exchange or for registration of transfer, duly
endorsed or with the form of transfer endorsed thereon duly
executed if so required by us or the security registrar, at the
office of the security registrar or at the office of any
transfer agent designated by us for this purpose. Unless
otherwise provided in the notes that the holder presents for
transfer or exchange, we will make no service charge for any
registration of transfer or exchange, but we may require payment
of any taxes or other governmental charges.
We will name in the applicable prospectus supplement the
security registrar, and any transfer agent in addition to the
security registrar, that we initially designate for any notes.
We may at any time designate additional transfer agents or
rescind the designation of any transfer agent or approve a
change in the office through which any transfer agent acts,
except that we will be required to maintain a transfer agent in
each place of payment for the notes of each series.
If we elect to redeem the notes of any series, we will not be
required to:
| • | issue, register the transfer of, or exchange any notes of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any notes that may be selected for redemption and ending at the close of business on the day of the mailing; or | |
| • | register the transfer of or exchange any notes so selected for redemption, in whole or in part, except the unredeemed portion of any notes we are redeeming in part. |
Information
Concerning the Debenture Trustee
The debenture trustee, other than during the occurrence and
continuance of an event of default under an indenture,
undertakes to perform only those duties as are specifically set
forth in the applicable indenture. Upon an event of default
under an indenture, the debenture trustee must use the same
degree of care as a prudent person would exercise or use in the
conduct of his or her own affairs. Subject to this provision,
the debenture trustee is under no obligation to exercise any of
the powers given it by the indentures at the request of any
holder of notes unless it is offered reasonable security and
indemnity against the costs, expenses and liabilities that it
might incur.
Payment
and Paying Agents
Unless we otherwise indicate in the applicable prospectus
supplement, we will make payment of the interest on any notes on
any interest payment date to the person in whose name the notes,
or one or more predecessor securities, are registered at the
close of business on the regular record date for the interest.
We will pay principal of and any premium and interest on the
notes of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in
the applicable prospectus supplement, will we make interest
payments by check which we will mail to the holder. Unless we
otherwise indicate in a prospectus supplement, we will designate
the corporate trust office of the debenture trustee in the City
of New York as our sole paying agent for payments with respect
to notes of each series. We will name in the applicable
prospectus supplement any other paying agents that we initially
designate for the notes of a particular series. We will maintain
a paying agent in each place of payment for the notes of a
particular series.
All money we pay to a paying agent or the debenture trustee for
the payment of the principal of or any premium or interest on
any notes which remains unclaimed at the end of two years after
such principal, premium or interest has become due and payable
will be repaid to us, and the holder of the security thereafter
may look only to us for payment thereof.
12
Table of Contents
Governing
Law
The indentures and the notes will be governed by and construed
in accordance with the laws of the State of New York, except to
the extent that the Trust Indenture Act is applicable.
Subordination
of Subordinated Notes
The subordinated notes will be unsecured and will be subordinate
and junior in priority of payment to certain of our other
indebtedness to the extent described in a prospectus supplement.
The subordinated indenture does not limit the amount of
subordinated notes which we may issue. It also does not limit us
from issuing any other secured or unsecured debt.
DESCRIPTION
OF WARRANTS
The following description, together with the additional
information we may include in any applicable prospectus
supplement, summarizes the material terms and provisions of the
warrants that we may offer under this prospectus and the related
warrant agreements and warrant certificates. While the terms
summarized below will apply generally to any warrants that we
may offer, we will describe the particular terms of any series
of warrants in more detail in the applicable prospectus
supplement. If we so indicate in the prospectus supplement, the
terms of any warrants offered under that prospectus supplement
may differ from the terms described below.
General
We may issue warrants for the purchase of common stock
and/or debt
securities in one or more series. We may issue warrants
independently or together with common stock
and/or debt
securities, and the warrants may be attached to or separate from
these securities.
We will evidence each series of warrants by warrant certificates
that we will issue under a separate agreement. We may enter into
the warrant agreement with a warrant agent. Each warrant agent
will be a bank that we select which has its principal office in
the United States and a combined capital and surplus of at least
$50,000,000. We will indicate the name and address of the
warrant agent in the applicable prospectus supplement relating
to a particular series of warrants.
We will describe in the applicable prospectus supplement the
terms of the series of warrants, including:
| • | the offering price and aggregate number of warrants offered; | |
| • | the currency for which the warrants may be purchased; | |
| • | if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; | |
| • | if applicable, the date on and after which the warrants and the related securities will be separately transferable; | |
| • | in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; | |
| • | in the case of warrants to purchase common stock, the number of shares of common stock purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; | |
| • | the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; | |
| • | the terms of any rights to redeem or call the warrants; |
13
Table of Contents
| • | any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; | |
| • | the dates on which the right to exercise the warrants will commence and expire; | |
| • | the manner in which the warrant agreement and warrants may be modified; | |
| • | federal income tax consequences of holding or exercising the warrants; | |
| • | the terms of the securities issuable upon exercise of the warrants; and | |
| • | any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
Before exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable
upon such exercise, including:
| • | in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or | |
| • | in the case of warrants to purchase common stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. |
Exercise
of Warrants
Each warrant will entitle the holder to purchase the securities
that we specify in the applicable prospectus supplement at the
exercise price that we describe in the applicable prospectus
supplement. Unless we otherwise specify in the applicable
prospectus supplement, holders of the warrants may exercise the
warrants at any time up to 5:00 P.M. New York City time on
the expiration date that we set forth in the applicable
prospectus supplement. After the close of business on the
expiration date, unexercised warrants will become void.
Holders of the warrants may exercise the warrants by delivering
the warrant certificate representing the warrants to be
exercised together with specified information, and paying the
required amount to the warrant agent in immediately available
funds, as provided in the applicable prospectus supplement. We
will set forth on the reverse side of the warrant certificate
and in the applicable prospectus supplement the information that
the holder of the warrant will be required to deliver to the
warrant agent upon exercise of the warrants.
Upon receipt of the required payment and the warrant certificate
properly completed and duly executed at the corporate trust
office of the warrant agent or any other office indicated in the
applicable prospectus supplement, we will issue and deliver the
securities purchasable upon such exercise. If fewer than all of
the warrants represented by the warrant certificate are
exercised, then we will issue a new warrant certificate for the
remaining amount of warrants. If we so indicate in the
applicable prospectus supplement, holders of the warrants may
surrender securities as all or part of the exercise price for
warrants.
Enforceability
of Rights by Holders of Warrants
Each warrant agent will act solely as our agent under the
applicable warrant agreement and will not assume any obligation
or relationship of agency or trust with any holder of any
warrant. A single bank or trust company may act as warrant agent
for more than one issue of warrants. A warrant agent will have
no duty or responsibility in case of any default by us under the
applicable warrant agreement or warrant, including any duty or
responsibility to initiate any proceedings at law or otherwise,
or to make any demand upon us. Any holder of a warrant may,
without the consent of the related warrant agent or the holder
of any other warrant, enforce by appropriate legal action its
right to exercise, and receive the securities purchasable upon
exercise of, its warrants.
14
Table of Contents
LEGAL
OWNERSHIP OF SECURITIES
We can issue securities in registered form or in the form of one
or more global securities. We describe global securities in
greater detail below. We refer to those persons who have
securities registered in their own names on the books that we or
any applicable trustee maintain for this purpose as the
“holders” of those securities. These persons are the
legal holders of the securities. We refer to those persons who,
indirectly through others, own beneficial interests in
securities that are not registered in their own names, as
“indirect holders” of those securities. As we discuss
below, indirect holders are not legal holders, and investors in
securities issued in book-entry form or in street name will be
indirect holders.
Book-Entry
Holders
We may issue securities in book-entry form only, as we will
specify in the applicable prospectus supplement. This means
securities may be represented by one or more global securities
registered in the name of a financial institution that holds
them as depositary on behalf of other financial institutions
that participate in the depositary’s book-entry system.
These participating institutions, which are referred to as
participants, in turn, hold beneficial interests in the
securities on behalf of themselves or their customers.
Only the person in whose name a security is registered is
recognized as the holder of that security. Securities issued in
global form will be registered in the name of the depositary or
its participants. Consequently, for securities issued in global
form, we will recognize only the depositary as the holder of the
securities, and we will make all payments on the securities to
the depositary. The depositary passes along the payments it
receives to its participants, which in turn pass the payments
along to their customers who are the beneficial owners. The
depositary and its participants do so under agreements they have
made with one another or with their customers; they are not
obligated to do so under the terms of the securities.
As a result, investors in a book-entry security will not own
securities directly. Instead, they will own beneficial interests
in a global security, through a bank, broker or other financial
institution that participates in the depositary’s
book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will
be indirect holders, and not holders, of the securities.
Street
Name Holders
We may terminate a global security or issue securities in
non-global form. In these cases, investors may choose to hold
their securities in their own names or in “street
name.” Securities held by an investor in street name would
be registered in the name of a bank, broker or other financial
institution that the investor chooses, and the investor would
hold only a beneficial interest in those securities through an
account he or she maintains at that institution.
For securities held in street name, we will recognize only the
intermediary banks, brokers and other financial institutions in
whose names the securities are registered as the holders of
those securities, and we will make all payments on those
securities to them. These institutions pass along the payments
they receive to their customers who are the beneficial owners,
but only because they agree to do so in their customer
agreements or because they are legally required to do so.
Investors who hold securities in street name will be indirect
holders, not holders, of those securities.
Legal
Holders
Our obligations, as well as the obligations of any applicable
trustee and of any third parties employed by us or a trustee,
run only to the legal holders of the securities. We do not have
obligations to investors who hold beneficial interests in global
securities, in street name or by any other indirect means. This
will be the case whether an investor chooses to be an indirect
holder of a security or has no choice because we are issuing the
securities only in global form.
For example, once we make a payment or give a notice to the
holder, we have no further responsibility for the payment or
notice even if that holder is required, under agreements with
depositary participants or customers or by law, to pass the
payment or notice along to the indirect holders but does not do
so. Similarly,
15
Table of Contents
we may want to obtain the approval of the holders to amend an
indenture, to relieve us of the consequences of a default or of
our obligation to comply with a particular provision of the
indenture or for other purposes. In such an event, we would seek
approval only from the holders, and not the indirect holders, of
the securities. Whether and how the holders contact the indirect
holders is the responsibility of the holders.
Special
Considerations for Indirect Holders
If you hold securities through a bank, broker or other financial
institution, either in book-entry form or in street name, you
should check with your own institution to find out:
| • | how it handles securities payments and notices; | |
| • | whether it imposes fees or charges; | |
| • | how it would handle a request for the holders’ consent, if ever required; | |
| • | whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; | |
| • | how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and | |
| • | if the securities are in book-entry form, how the depositary’s rules and procedures will affect these matters. |
Global
Securities
A global security is a security held by a depositary which
represents one or any other number of individual securities.
Generally, all securities represented by the same global
securities will have the same terms.
Each security issued in book-entry form will be represented by a
global security that we deposit with and register in the name of
a financial institution or its nominee that we select. The
financial institution that we select for this purpose is called
the depositary. Unless we specify otherwise in the applicable
prospectus supplement, The Depository Trust Company, New
York, New York, known as DTC, will be the depositary for all
securities issued in book-entry form.
A global security may not be transferred to or registered in the
name of anyone other than the depositary, its nominee or a
successor depositary, unless special termination situations
arise. We describe those situations below under “Special
Situations When a Global Security Will Be Terminated.” As a
result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and holder of all securities
represented by a global security, and investors will be
permitted to own only beneficial interests in a global security.
Beneficial interests must be held by means of an account with a
broker, bank or other financial institution that in turn has an
account with the depositary or with another institution that
does. Thus, an investor whose security is represented by a
global security will not be a holder of the security, but only
an indirect holder of a beneficial interest in the global
security.
If the prospectus supplement for a particular security indicates
that the security will be issued in global form only, then the
security will be represented by a global security at all times
unless and until the global security is terminated. If
termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no
longer be held through any book-entry clearing system.
Special
Considerations for Global Securities
As an indirect holder, an investor’s rights relating to a
global security will be governed by the account rules of the
investor’s financial institution and of the depositary, as
well as general laws relating to securities transfers. We do not
recognize an indirect holder as a holder of securities and
instead deal only with the depositary that holds the global
security.
16
Table of Contents
If securities are issued only in the form of a global security,
an investor should be aware of the following:
| • | an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below; | |
| • | an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe under “Legal Ownership of Securities” above; | |
| • | an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; | |
| • | an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; | |
| • | the depositary’s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor’s interest in a global security. We and any applicable trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way; | |
| • | the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and | |
| • | financial institutions that participate in the depositary’s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. |
Special
Situations When a Global Security Will Be Terminated
In a few special situations described below, the global security
will terminate and interests in it will be exchanged for
physical certificates representing those interests. After that
exchange, the choice of whether to hold securities directly or
in street name will be up to the investor. Investors must
consult their own banks or brokers to find out how to have their
interests in securities transferred to their own name, so that
they will be direct holders. We have described the rights of
holders and street name investors above.
The global security will terminate when the following special
situations occur:
| • | if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; | |
| • | if we notify any applicable trustee that we wish to terminate that global security; or | |
| • | if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. |
The prospectus supplement may also list additional situations
for terminating a global security that would apply only to the
particular series of securities covered by the prospectus
supplement. When a global security terminates, the depositary,
and not we or any applicable trustee, is responsible for
deciding the names of the institutions that will be the initial
direct holders.
PLAN OF
DISTRIBUTION
We may sell or issue the securities being offered hereby in one
or more of the following ways from time to time:
| • | through dealers or agents to the public or to investors; |
17
Table of Contents
| • | to underwriters for resale to the public or to investors; | |
| • | directly to investors or others with whom we have business relationships; or | |
| • | through a combination of such methods. |
We will set forth in a prospectus supplement the terms of the
offering of securities, including:
| • | the name or names of any agents, dealers or underwriters; | |
| • | the purchase price of the securities being offered and the proceeds we will receive from the sale; | |
| • | any over-allotment options under which underwriters may purchase additional securities from us; | |
| • | any agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation; | |
| • | any initial public offering price; | |
| • | any discounts or concessions allowed or reallowed or paid to dealers; and | |
| • | any securities exchanges on which the securities may be listed. |
Underwriters, dealers and agents that participate in the
distribution of the securities may be deemed to be underwriters
as defined in the Securities Act and any discounts or
commissions they receive from us and any profit on their resale
of the securities may be treated as underwriting discounts and
commissions under the Securities Act. We will identify in the
applicable prospectus supplement any underwriters, dealers or
agents and will describe their compensation. In compliance with
guidelines of the Financial Industry Regulatory Authority
(FINRA), the maximum compensation to be received by any FINRA
member or independent broker dealer may not exceed 8% of the
gross proceeds received by us in connection with the sale of any
securities offered pursuant to this prospectus and any
applicable prospectus supplement. We may have agreements with
the underwriters, dealers and agents to indemnify them against
specified civil liabilities, including liabilities under the
Securities Act. Underwriters, dealers and agents may engage in
transactions with or perform services for us or our subsidiaries
in the ordinary course of their businesses.
Certain persons that participate in the distribution of the
securities may engage in transactions that stabilize, maintain
or otherwise affect the price of the securities, including
over-allotment, stabilizing and short-covering transactions in
such securities, and the imposition of penalty bids, in
connection with an offering. Certain persons may also engage in
passive market making transactions as permitted by Rule 103
of Regulation M. Passive market makers must comply with
applicable volume and price limitations and must be identified
as passive market makers. In general, a passive market maker
must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are
lowered below the passive market maker’s bid, however, the
passive market maker’s bid must then be lowered when
certain purchase limits are exceeded.
LEGAL
MATTERS
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
Boston, Massachusetts, will provide us with an opinion as to the
legal matters in connection with the securities we are offering.
EXPERTS
The financial statements of OXiGENE, Inc. appearing in OXiGENE,
Inc.’s Annual Report
(Form 10-K)
for the year ended December 31, 2007, and the effectiveness
of OXiGENE, Inc.’s internal control over financial
reporting as of December 31, 2007, have been audited by
Ernst & Young LLP, independent registered public
accounting firm, as set forth in their reports thereon, included
therein, and incorporated herein by reference. Such financial
statements are, and audited financial statements to be included
in subsequently filed documents will be, incorporated herein in
reliance upon the reports of Ernst & Young LLP
pertaining to such financial statements and the effectiveness of
our internal control over financial reporting as of the
respective
18
Table of Contents
dates (to the extent covered by consents filed with the
Securities and Exchange Commission) given on the authority of
such firm as experts in accounting and auditing.
WHERE YOU
CAN FIND MORE INFORMATION
We are a public company and file annual, quarterly and current
reports, proxy statements and other information with the SEC.
You may read and copy any document we file at the SEC’s
Public Reference Room at Station Place, 100 F Street,
N.E., Washington, D.C. 20549. You can request copies of
these documents by writing to the SEC and paying a fee for the
copying cost. Please call the SEC at
1-800-SEC-0330
for more information about the operation of the Public Reference
Room. Our SEC filings are also available to the public at the
SEC’s web site at
http://www.sec.gov,
and on our web site at
http://www.oxigene.com.
The information contained on our web site is not included or
incorporated by reference into this prospectus, nor will it be
incorporated by reference into any prospectus supplement. In
addition, our common stock is listed for trading on The NASDAQ
Global Market under the symbol “OXGN.” You can read
and copy reports and other information concerning us at the
offices of the Financial Industry Reporting Authority located at
1735 K Street, N.W., Washington, D.C. 20006.
This prospectus is only part of a Registration Statement on
Form S-3
that we have filed with the SEC under the Securities Act, and
therefore omits certain information contained in the
Registration Statement. We have also filed exhibits and
schedules with the Registration Statement that are excluded from
this prospectus, and you should refer to the applicable exhibit
or schedule for a complete description of any statement
referring to any contract or other document. You may:
| • | inspect a copy of the Registration Statement, including the exhibits and schedules, without charge at the Public Reference Room, | |
| • | obtain a copy from the SEC upon payment of the fees prescribed by the SEC, or | |
| • | obtain a copy from the SEC’s web site or our web site. |
INCORPORATION
OF CERTAIN DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” the
information we file with it, which means that we can disclose
important information to you by referring you to those
documents. The information incorporated by reference is
considered to be part of this prospectus and information we file
later with the SEC will automatically update and supersede this
information. We incorporate by reference the documents listed
below and any future filings made by us with the SEC under
Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).
The documents we are incorporating by reference as of their
respective dates of filing are:
| • | Our Annual Report on Form 10-K for the year ended December 31, 2007 filed on March 14, 2008 (File No. 000-21990); | |
| • | Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2008 filed on May 12, 2008 (File No. 000-21990); | |
| • | Our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2008 filed on August 8, 2008 (File No. 000-21990); | |
| • | Our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2008 filed on November 7, 2008 (File No. 000-21990); | |
| • | Our Current Report on Form 8-K filed on February 21, 2008 (File No. 000-21990); | |
| • | Our Current Report on Form 8-K filed on July 15, 2008 (File No. 000-21990); | |
| • | Our Current Report on Form 8-K filed on October 1, 2008 (File No. 000-21990); | |
| • | Amendment No. 1 to our Current Report on Form 8-K/A filed on October 10, 2008 (File No. 000-21990); |
19
Table of Contents
| • | Our Current Report on Form 8-K filed on October 24, 2008 (File No. 000-21990); | |
| • | Our Current Report on Form 8-K filed on October 27, 2008 (File No. 000-21990); | |
| • | Our Definitive Proxy Statement on Schedule 14A for the 2008 annual meeting of stockholders filed on April 28, 2008 (File No. 000-21990); | |
| • | The description of our common stock contained in our Registration Statement on Form 8-A filed on June 24, 1993 (File No. 0-21990) pursuant to Section 12(g) of the Exchange Act, which incorporates by reference the description of the shares of our common stock contained in our Registration Statement on Form S-1 (File No. 33-64968) filed on June 24, 1993 and declared effective by the SEC on August 25, 1993, including any amendment or reports filed for the purpose of updating such description; and | |
| • | The description of the Rights under the Stockholder Rights Agreement (which are currently transferred with the Registrant’s common stock) contained in the Registrant’s Registration Statement on Form 8-A12G (File No. 000-21990) filed under the Exchange Act on March 30, 2005, including any amendment or reports filed for the purpose of updating such description. |
You may request, orally or in writing, a copy of these filings,
which will be provided to you at no cost, by contacting our
investor relations department at our principal executive
offices, which are located at 230 Third Avenue, Waltham, MA
02451, Attention: Investor Relations, Telephone:
(781) 547-5900.
To the extent that any statements contained in a document
incorporated by reference are modified or superseded by any
statements contained in this prospectus, such statements shall
not be deemed incorporated into this prospectus except as so
modified or superseded.
We also incorporate by reference all documents subsequently
filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d)
of the Exchange Act, including all such documents filed after
the date of the initial registration statement and prior to
effectiveness of the registration statement, and all such
documents filed after the date of this prospectus and prior to
the termination of this offering, which documents shall become a
part of this prospectus from the date such documents are filed.
Any statement contained in this prospectus or in a document
incorporated by reference is modified or superseded for purposes
of this prospectus to the extent that a statement contained in
any subsequent filed document modifies or supersedes such
statement.
20